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ABSTRACT 
Influenza is a respiratory disease that infects 0.4-0.6 billion children and 0.2-5.0 billion 
adults worldwide. In addition to seasonal influenza, pandemic strains can infect a large number 
of people rapidly. Rapid and precise detection of influenza viruses is critical for appropriate 
interventions. Current methods such as cell culture and PCR are expensive and require well-
trained personnel. Antibody based tests are not sensitive. Herein, we have designed and 
synthesized an influenza specific substrate 4,7di-OMeSα2,3/6Gal, and developed an assay that 
uses a portable potentiostat and commercial Accu-Chek strips. We demonstrated that this assay 
detects the influenza virus with high specificity within 15 minutes.  This strategy can also be 
used to detect glycosidases, which in turn could be useful to report the presence of a pathogen or 
illness. 
Plasmodium falciparum GPIs have been considered as potential vaccine candidates 
because these molecules are involved in inducing inflammatory responses in human hosts, and 
natural anti-GPI antibody responses have been shown to be associated with protection against 
severe disease. GPIs can also be considered as targets for rapid diagnostic tests. Here, we report 
synthesis and immunological characterization of a panel of malaria-specific GPI analogues, 
which is conjugated to a carrier protein to immunize and generate antibodies in rabbits. The 
rabbit immune sera showed reactivity with synthetic GPIs and native GPIs extracted from P. 
falciparum parasite, as determined by Luminex and ELISA methods. 
Bioorthogonal chemistry is playing an important role in labeling and imaging live cells, 
especially the tetrazine and TCO based IEDDA reaction. Herein, we designed a bioorthogonal 
amplification system to increase the assay sensitivity. The data shows our proposed amplification 
system works in assays, and modifications are in progress. 
INDEX WORDS: Influenza, Neuraminidase, Glycosidase, GPI anchor, bioorthogonal, tetrazine, 
TCO.  
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1 CHAPTER 1 POINT OF CARE DETECTION 
1.1 Introduction 
Point-of-care diagnostics (POCD) are composed of tests that are performed near the patient 
which requires a quick turn-around time and do not require permanent space in a clinical 
laboratory. It is essential for the rapid detection of analytes near to the patient, which assists better 
disease diagnosis, monitoring, and management. It enables quick medical decisions, as the diseases 
can be diagnosed at a very early stage, leading to the early start of treatment1. The global POCD 
market is expected to reach $ 38.13 billion by 2022 from $ 23.17 billion in 2017 with an 
approximately 10.00% increase annually during this period2. North America accounts for the 
largest share of the point-of-care diagnostics market, followed by Europe, Asia Pacific and the rest 
of the world (Figure 1-1). 
 
Figure 1-1 Worldwide point-of-care diagnostics market. Data was adopted online2. 
Several prospective POCD have been developed during recent years, which are paving the 
way to next-generation POCT3.  The diabetes is still the primary driver of the POCD market. The 
45%
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5%
Worldwide POCD Market
North America Asia Pacific Europe Rest of World
2 
most critical component of POCD is the biosensors, which are directly responsible for the assay 
performance. Several outstanding label-free biosensors, such as electrochemical, surface plasmon 
resonance (SPR), PCR, have been developed, and are being used for improved POCD. 
Complementary technologies, such as microfluidics, lab-on-a-chip technologies, system 
integration, device automation, and signal readout, are providing the desired impetus for 
continuous improvements in POCD1. 
Two broad types of technology support point-of-care testing: small handheld, single use 
devices including quantitative and qualitative strips (such as urine, blood glucose, and coagulation 
tests), and larger bench top analyzers (blood gas and electrolyte systems). The bench top systems 
are smaller versions of laboratory analyzers and some of the steps have been set up automatically, 
for example, flushing of sample after analysis, calibration, and quality control. Handheld devices 
have been developed using microfabrication techniques. They are outwardly simple but internally 
complex devices that do several tasks—for example, separate cells from plasma, add reagents, and 
read fluorescence or other end points such as current. 
An ideal POCD device should meet ASSURED criteria, which was provided by World 
Health Organization (WHO) for the developing of POCD device for the detection of sexually 
transmitted diseases (STDs)4. These ASSURED criteria is shown in Table 1-1. 
Table 1-1 ASSURED criteria for the design of POCD devices 
Affordable For those with high risk of infections 
Sensitive Minimum false negative 
Selective Minimum false positive 
User friendly Easy to handle 
Rapid and Robust Short test time and no refrigerated storage 
3 
Equipment free No complex equipment 
Deliverable to end-users 
 
1.2 Point-of-care Applications 
1.2.1 Home Care 
The most commonly used POCD devices at home care are glucose meters and urine 
dipsticks (Figure 1-2). Diabetes is a worldwide public health problem, and currently the diabetes 
patients are still the leading driver of the POCD market. The diabetes patient needs to measure the 
blood glucose concentration levels several time one day. Glucose meters play a very important 
role in this direction. Current models reflect several decades of innovation since their introduction 
in the 1970s, both in terms of strip technology and also in meter design5. The overall goals have 
switched to make them easier to use, with less potential errors, and to minimize the effects of 
matrixs6. Of the many different types of strip that have been developed, all are electrochemical 
biosensors incorporating an enzyme such as glucose oxidase (GOx) and glucose dehydrogenase 
(GDH). They are often termed thick-film sensors because each strip is composed of several layers 
each with designated functions such as separation, spreading or support. Besides diabetes patients, 
glucose meter can be also used by hypoglycemia patients. 
Urine dipsticks is another widely used POCD device at home. The most classic example 
of urine dipsticks is pregnancy test strips. Lateral flow assay is the core of these POCD device. 
The compounds present in the strips react with certain compounds in urine leading to color change 
in the strips. There are usually two lines in the pregnancy test strips, named as control line and test 
line. Control line will change color each time when you use it to demonstrate the assay is working. 
4 
The test line will only change color when the product binds to the antibody present on it. Only 
when the test line and control line both change colors, it indicates that you are pregnant.  
 
Figure 1-2 Glucose meter and pregnancy test strips7,8. 
1.2.2 Physician office / Urgent care 
Point-of-care diagnostics offers a number of potential advantages in primary care, 
including earlier diagnosis, communication with patients, and disease management, with 
potential to improve patient satisfaction and affordable cost. Other potential advantages include 
reducing health inequalities by being accessible to certain hard to reach socioeconomic or ethnic 
groups9. Use of simple urine testing strips and blood glucose measurements are routine in 
primary care, although more sophisticated near-patient tests have been limited to anticoagulant 
monitoring, diabetes management, and testing for C reactive proteins10. 
In the physician office / urgent care, POCD is used to test respiratory infections such as 
influenza (Figure 1-3)11, group A streptococcus12, malaria13, tuberculosis14 and parainfluenza15. 
With the detection of POCD, patient can be diagnosed at early stage of infectious disease, and 
lead to prompt treatment.  
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Figure 1-3 Commercially available point-of-care diagnostics instrument for detection of 
influenza (AlereTM-i)16.  
1.2.3 Accident and Emergency Department  
Point-of-care tests have great potential for facilitating faster decision making and therefore 
more effective patient triage in the accident and emergency department. The main studies in 
accident and emergency department have been focused on tests for measuring blood gas and 
cardiac marker. Point-of-care detection can reduce the length of stay at emergency department, 
therefore lead to earlier treatment. Rapid analysis of cardiac markers may improve the recognition 
of patients who will benefit from early treatment as well as those who are at greatest risk of a later 
cardiac event.  
1.3 Point-of-care Technology 
Since the biosensors are the most important component of POCD devices, more and more 
attention has been paid to the development of new biosensors in these years. Currently the most 
widely used label-free biosensors are based on electrochemistry, optical or loop-mediated 
isothermal amplification (LAMP). 
1.3.1 Electrochemistry 
Electrochemistry is the study of chemical processes that cause electrons to move. It can be 
generated by movements of electrons from one element to another in a reaction known as an 
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oxidation-reduction (redox) reaction. For example, Zn + 2HCl = ZnCl2 + H2, the oxidation reaction 
is Zn  Zn2+ + 2e and the reduction reaction is 2H+ + 2e  H2. 
The most classical example of POCD devices based on electrochemistry is glucose meter, 
which can convert current to blood glucose concentration with inner calibration.  There are usually 
three electrodes in the printed glucose test strips, which are working electrode, reference electrode 
and counter electrode. For some glucose test strips such as Accu-Chek strips, the counter electrode 
and reference electrode are combined into one electrode in the strips. All the electrodes are working 
together to automatically calibrate, detect and convert the electric current to readings.  
Of the many different types of strip that have been developed, all are biosensors 
incorporating an enzyme such as glucose oxidase (GOx), glucose dehydrogenase (GDH) or 
hexokinase. Strips that use glucose oxidase are more substrate-specific but are affected by oxygen 
tension, with high PO2 values leading to falsely low results. Blood oxygen tension does not affect 
GDH-based strips but GDH strips that use the pyrroloquinolinequinone form of the enzyme are 
subject to interference by maltose5. 
The chemistry behind glucose meters are discussed below as in Figure 1-4. For the testing 
of blood glucose concentration, typically one drop of blood is needed. The enzyme GOx present 
on the strips oxidizes glucose to gluconolactone and the cofactor FAD is reduced to FADH2, which 
is further reoxidizes to FAD by oxygen in air and generate hydrogen peroxide.  Hydrogen peroxide 
can oxidize Prussian white to Prussian blue, which can be further reduced to Prussian white on the 
electrode by electron gaining at a low potential17. Then this electron can be captured by a 
potentiostat or a glucose meter. 
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Figure 1-4 The chemistry principle of glucose meters. 
1.3.2 Optical 
Optical based biosensors are another category of label-free biosensors. Of the optical based 
biosensors, the lateral flow assay plays an important role. It is a paper-based device which is 
designed to detect the present or absent of an analyte in the liquid sample, such as urine. It is widely 
used by the patients at hospital or at home. The most widely known and used example is pregnancy 
test. 
There are several components in lateral flow assay, as shown in Figure 1-518. The first 
element is the sample pad, which can hold all the samples need to analyze. The second element is 
called conjugate pad, where the analyze reacts with primary antibody to form measurement 
complex. With capillary flow, the complex reaches the Test line, and finally Control line. In test 
line, the secondary antibody has been immobilized by the manufacturer. By the time the sample-
conjugate complex reaches the test line, the analyze-primary antibody will bound to secondary 
antibody. After a while, when more and more fluid has passed the test line, the test line changes 
color. The control line contains a specific capture molecule and only captures those particles onto 
which an analyte molecule has been immobilized. After passing these reaction zones, the fluid 
enters the final element, the wicking pad that simply acts as a waste container. 
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Figure 1-5 The lateral flow assay16, 19. 
1.3.3 Loop-mediated isothermal amplification (LAMP) 
Loop-mediated isothermal amplification (LAMP) is an isothermal amplification of DNA 
technology, which is an ideal amplification technology for developing POCD devices because it 
fulfill the ASSURED criteria20. Compared to PCR which requires several thermal cycles and takes 
a longer time (~1 h), LAMP is amplified at one temperature and the amplification process is rapid 
(less than 30 min). LAMP can also be used to amplify RNA by utilizing reverse transcriptase. 
In LAMP, a DNA polymerase and typically 4 different specially designed primers are 
needed, as shown in Figure 1-620. The primers can recognize a total of six distinct sequences on 
the target DNA, which are contributed to the high selectivity of LAMP. The LAMP is initiated by 
an inner primer which contains sequences of the target DNA. The outer primer catalyzes the 
synthesis of strand displacement DNA and release a single-strand DNA, which serves as template 
for DNA synthesis primed by the second inner and outer primers that hybridized to the other end 
of the target to produce a stem-loop DNA structure. In the LAMP cycling, one inner primer 
hybridizes to the loop on the product and initiates displacement DNA synthesis to yield the original 
stem-loop DNA and a new stem-loop DNA with a stem twice as long. Due to the specific nature 
of the action of these primers, the amount of DNA produced in LAMP can achieve 109 copies of 
target in less than 1 h, which is much higher than PCR based amplification. 
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Figure 1-6 The principle of LAMP. 
AlereTM-i is a famous example of POCD device which uses LAMP technology for the 
detection of influenza A and B in doctor’s office, or even at home.  AlereTM-I can provide the 
results within just a few minutes, which can lead to earlier detection and therapeutics. 
1.3.4 GeneXpert technology 
The GeneXpert system was first launched in 2004 for the diagnostics of Mycobacterium 
tuberculosis (TB) by detecting the gene of TB bacteria, no matter it is alive or dead21. It can be 
also used to test the resistance to the drug Rifampicin. WHO recommended that the GeneXpert 
test should be used as the initial diagnostics test for people who have MDR TB or HIV 
associated TB. Since it was launched, to date, it has been widely applied to detect other 
pathogens or infections, such as Clostridium difficile, flu, Streptococcus pneumoniae A, and 
STDs22.  
The GeneXpert test is a cartridge based automated nucleic acid amplification test, it is 
based on the real time PCR to amplify the sequence of the gene. The typical turnover time is less 
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than 2 hours. For the detection of influenza and Streptococcus pneumoniae A, the results can be 
provided within 45 min. The cost of the GeneXpert is approximately $10. It is highly sensitive 
and specific to the diseases because it detect the gene information of the pathogens. 
Although the GeneXpert technology is great, however, there are still some limitations. 
The shelf life of the cartridges is only 18 months, and it requires a kind of very stable electricity 
supply. The instrument needs to be recalibrated every year. The cost of the test is not as cheap as 
glucose meters. 
1.4 Summary 
The development of point-of-care diagnostics device has expanded considerably in the last 
few decades, driven by the need of diagnostics closer to the patient. More and more technologies 
and biosensors are discovered and used in the new generation of point-of-care diagnostics devices. 
Electrochemistry, optical, LAMP, and GeneXpert system are still the main technology used in the 
POCD devices, as shown in table 1-2. However, how to improve the sensitivity and selectivity and 
reduce the waiting-time is still a problem. One solution is that to find new specific target of disease. 
To solve the waiting-time problem, amplification is a good option. Our group is working on the 
bioorthogonal chemistry based amplification, based on the rapid ligation of tetrazine and trans-
cyclooctene.  
Table 1-2 The list of POCD technology under ASSURED criteria. 
ASSURED Glucose meter Lateral flow assay LAMP GeneXpert 
Affordable Yes Yes No No 
Sensitive High Low High High 
Selective High High High High 
User-friendly Yes Yes Yes Yes 
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Rapid & Robust Yes Yes 30 min 45min ~ 2 h 
Equipment-free Yes Yes No No 
Deliverable Yes Yes Yes No. 
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2 CHAPTER 2. HIGHLY SPECIFIC AND RAPID GLYCAN BASED 
AMPEROMETRIC DETECTION OF INFLUENZA VIRUSES 
2.1    Introduction 
2.1.1   Influenza History 
Influenza is a respiratory disease which affects millions of people worldwide annually. In 
addition to seasonal influenza, pandemics strains can affect a large number of people rapidly. 
The first major influenza pandemic was reported in 1918 (H1N1), also known as the Spanish flu, 
which infected approximately one third of the world’s population, and led to estimated up to 50 
million23.  After the 1918 pandemic, there were no major pandemics for almost 30 years.  In 
1957, Asian influenza (H2N2) outbreak led to approximately 1 million to 4 million deaths 
worldwide in a very short time. The Asian influenza strain (H2N2) had a short life span and 
disappeared in only 1 year. 
It is not until another decade later that another influenza pandemic occurred.  The 
outbreak of 1968 (H3N2) in Hong Kong spread to Europe and America.  This strain caused 
severe damage in the United States and led to 33,800 people died.  It took another decade for the 
1977 pandemic (H1N1) to arrive, but this strain was a juvenile age-restricted strain.  The most 
recent pandemic occurred in 2009 (H1N1, swine flu).  The first case reported in the United States 
was in April 2009, and by June 2009, 18,000 new cases were reported24. It spread to 74 countries 
within less than two months, and finally infected over 200 countries worldwide. 
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Table 2-1 Deaths and infections rate associate with influenza A virus25 
Pandemic Death Fatality Rate 
Spanish flu (1918-1920) 20~100 million 2% 
Asian flu (1957-1958) 1~1.5 million 0.13% 
Hong Kong flu (1968-1969) 0.75~1 million <0.1% 
2009 flu pandemic 18,000~284,500 0.03% 
 
2.1.1 Classification of Influenza 
        Influenza virus is classified into four types, influenza A, B, C and D.  Type A and B 
are most important due to their ability to cause seasonal epidemics. Influenza C is usually only 
associated with minor symptoms. Influenza type D was found to infect cattle, but not known to 
infect humans.  
       Influenza type A can be further spilt into subtypes according to their two surface 
proteins: Hemagglutinin (HA) and Neuraminidase (NA). There are 18 subtypes of hemagglutinin 
and 11 subtypes of neuraminidase.  
       Influenza virus was first isolated from swine in the late 1920s, followed by the first 
virus isolation from humans in 1933. Influenza virus belongs to the Orthomyxoviridae family and 
is characterized by the presence of eight segmented negative strand RNA26. These single stranded 
RNA encoded for about 10 viral proteins. Amid the 8 single-stranded RNA, the two shortest are 
associated with nucleoproteins (NP) and all three P proteins (PB1, PB2 and PA)27. These proteins 
are viral machinery for RNA replications and transcriptions.  
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2.1.2  Life Cycle of Influenza 
      The cycle of influenza starts when HA binds to the sialic acid, which is the cellular 
receptor.  These sialic acids are the terminal carbohydrates bound to glycolipids or glycoproteins 
located on the cell surface. Upon binding to the host cell’s sialic acid residues, receptor-mediated 
endocytosis occurs and the virus enters the host cell in an endosome. The endosome has a low pH 
of around 5 to 6, which triggers the fusion of the viral and endosomal membranes. The fusion of 
viral and endosome results in the release of viral RNA into the cytoplasm.   
        When viral RNA is released into the cytoplasm, it must enter the nucleus where 
transcription and replication occurs. Once the RNA is replicated, the packaging and processing 
occurs and the viral progeny leaves the cell to infect other cells. Influenza viruses leave the cells 
via a process called budding.  The influenza virus is an envelope virus, therefore, in the process of 
budding it uses the plasma membrane of the host cells to form its envelope. The surface of these 
newly formed viral particles contains all the required proteins to leave the host cells.  In the process 
of leaving the host cell, another surface protein – Neuraminidase plays an important role. The 
function of NA is to cleave terminal sialic acid from glycoproteins and glycolipids to release the 
newly formed viral particles to go and infect other cells.  
2.1.3 Influenza viral proteins  
        There are two important proteins on the influenza virus surface, which are 
Hemagglutinin (HA), and Neuraminidase (NA).  
Hemagglutinin (HA) 
HA is a receptor-binding glycoprotein that are composed of three identical subunits and is 
anchored on the surface of the influenza virus28. It is responsible for the virus entering the host cell 
by binding to the residual sialic acid which is conjugated to 3 or 6 position of galactose present in 
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glycolipids or glycoproteins. And also it is important to the fusion of envelope viral and endosome 
membrane. HA proteins are classified into 18 different subtypes. HA from different source binds 
to different linkage of sialic acid. For example, HA from the avian recognize α 2,3 linkage, while 
HA from human prefers Sα2,6Gal linkage. However, HA from swine recognize both linkage. 
 
 
Figure 2-1 Hemagglutinin. A) Schematic showing the relationship between HA from 
different source.  Avian HA recognize Sα2,3Gal linkage, while human HA prefers Sα2,6Gal 
linkage. Swine HA binds both. B) Side and overhead view of the 1918’s H1 HA. C) Receptors 
recognized by HA’s of different lineage. 
Neuraminidase (NA) 
NA is the other major surface glycoprotein of influenza virus.  NA is a tetramer which is 
made up of four identical subunits with the molecular weight of approximately 240kD29. There are 
usually 50~100 copies of NA on virus surface. NA is essential for the influenza virus leaving the 
host cell by catalyzing hydrolysis of both α2,3 and α2,6 linkages of glycosidic bonds.   
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Figure 2-2 Three dimensional structure of neuraminidase. A) Overhead view of NA 
tetramer.  B) Overhead view of a single unit of NA with binding site. 
NA is an exoglycohydrolase which hydrolyzes terminal sialic acid residues from 
glycoproteins and glycoconjugates30. The hydrolysis mechanism is shown below (Figure 2-3)31. 
Cleavage of terminal sialoside initiate with the binding to the active sites of NA.  After binding, 
the stable chair conformation is forced into a less stable boat conformation due to the highly 
conserved triarginyl cluster (Arg-118, Arg-292, and Arg-371). Conformational changes facilitate 
the leaving group falling down and form an oxocarbocation ion intermediate, a sialosyl cation. The 
sialosyl cation undergoes a nucleophilic attack to form a glycosyl-enzyme intermediate. The 
glycosyl-enzyme intermediate breaks to generate a sialosyl cation again, where it undergoes 
nucleophilic attack by a water molecule to form an α-Neu5aAc as the initial product. The α-
Neu5Ac product is further isomerize into β-Neu5Ac, the more thermodynamically favored 
product.  
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Figure 2-3 The mechanism of NA catalyzed hydrolysis of sialosides31. 
2.1.4 Current diagnostics of influenza 
 Early, rapid and precise detection of influenza viruses is critical for applying 
appropriate countermeasures. There are several diagnostic methods for the accurate detection of 
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influenza virus.  These tests can range from viral culture, rapid diagnostic kits and real-time reverse 
transcriptase polymerase chain reaction (RT-PCR).  Although viral culture is highly sensitive and 
selective, it requires well-trained personnel, laboratory and takes days to get result.  PCR, as the 
golden standard, has become the most sensitive and selective diagnostics method of influenza 
virus, however, it needs well-trained personnel and expensive. Rapid diagnostics kits are faster, 
but suffer from low sensitivity. The comparison of these three diagnostics methods are list in Table 
2.2. 
Table 2-2 Current diagnostics of influenza virus. 
ASSURED Criteria Viral Culture RT-PCR RDTs 
Affordable YES NO YES 
Sensitive HIGH HIGH LOW 
Selective HIGH HIGH HIGH 
User-friendly NO NO YES 
Rapid & Robust NO NO YES 
Equipment free NO NO YES 
Deliverable NO NO YES 
 
2.1.6 Therapeutics of influenza  
To date, several methods such as vaccine and antiviral drugs, have been developed to treat 
influenza. Generally, these methods have been shown to cure the influenza, however as influenza 
virus mutates, some methods are no longer effective. 
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Vaccines 
 Seasonal flu led to approximately 200,000 hospitalizations and 36,00 deaths 
annually in the US, therefore there are high demand to find effective vaccines.  Vaccine is a good 
method to control the spread of influenza, not only because of the cost, but also the resistance 
strains.  Vaccination generates antibodies that mainly target on HA. As influenza antibodies mainly 
recognize specific regions on the globular head of the HA, their efficiency relies on the similarities 
between the HA of the vaccines and the seasonal strains.  Because of this, it is not easy to predict 
the coming seasonal strains, which becomes problematic to produce vaccines. Even though, it is 
still recommended to have influenza vaccines at the flu season. 
Antiviral Drugs 
 Another important method to treat influenza is anti-influenza drugs. There are 
several different types of drugs have been discovered.  
First Class of Antiviral drugs- M2 channel inhibitors 
 M2 channel protein is another essential protein on the influenza virus surface. The 
M2 ion channel is responsible for transporting protons to facilitate dissociation of viral particle 
and the release of viral genome32. This process is crucial for viral infections, therefore, it is the 
first target of antiviral drugs. The first class of antiviral drugs are amantadine and its analogues. 
However, as the influenza virus mutates, they are not effective now.  Over 90% of the influenza A 
has shown resistance to this class of antivirals.  Therefore, the Centers for Diseases Control and 
Prevention (CDC) doesn’t recommend to use them. 
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Figure 2-4 Structures of M2 inhibitors - Amantadine and Rimantadine. 
Second Class of Antiviral drugs – NA inhibitors  
 Zanamivir and Oseltamivir are two commonly used antiviral drugs now, which 
target on NA. They are more effective and less resistant. Zanamivir is a sialic acid analogue (2-
deoxy-α-D-Nacetylneuraminc acid) that has a guanidine function at the 4 position.  Oseltamivir is 
a cyclohexene derivative that contains an amino function at the 4 position.  
 
Figure 2-5 Structures of A) Sialic acid.  B)  Deoxy form of sialic acid with hydroxy group 
at the 4 position.  C)  Zanamivir.  D)  Oseltamivir.. 
 Zanamivir and Oseltamivir both were approved by the FDA in 1999 and very few 
strains of viruses have shown resistance.  Zanamivir is licensed under the trade name of Relenza 
and Oseltamivir is licensed under Tamiflu.  
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Figure 2-6 Neuraminidase inhibitors recently approved by the Food and Drug 
Administration (FDA) in 2012. 
With the demand for more effective drugs to combat the annual influenza outbreak and 
potentialpademics, there are new drugs that was recently approved in 2012.  Peramivir (Rapiacta®, 
Peramiflu®, BioCryst Pharmaceuticals, Research Triangle Park, North Carolina, USA) is among 
one of the drugs that was in phase III clinical trials and was approved for used during the 2009 
H1N1 influenza outbreak under the Emergency Investigational New Drug (eIND) regulations33.  
Peramivir, unlike traditional NA inhibitors, it has a unique structure differ from known NA 
inhibitors.  This NA inhibitor exhibitshigh binding affinity that last up to 24 hours and has a slow 
dissociation. Premavir has been approved for the treatment of influenza in both Japan and South 
Korea.  Unlike Zanamivir and Oseltamivir, Peramivir is administered through IV with the dosage 
of approximately 12mg/kg.   
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Figure 2-7 Laninaivir and its pro-drug structure. 
Laninamivir, like Zanamivir, is administered through an inhaler and was approved for use 
in Japan in 2010.  Researchers have also developed a pro-drug form of Laninamivir by introducing 
an 8-carbon chain at the 9-position via an ester bond.  The pro-drug form of Laninamivir is 
currently under clinical trials and have shown to have a half-live of approximately 41.4 hours in 
mice34.  Other studies with healthy volunteers have demonstrated that Laninamivir pro-drug was 
slowly excreted from the body in a span of six days from one inhalation in healthy human 
volunteers. The long excretion time is due to the body hydrolyzing the long carbon chain to activate 
the pro-drug to its’ active form Laninamivir. 
2.1.7Summary 
 Influenza virus affect millions worldwide annually.  Therefore, it has been extensively 
studied and still being studied for more effective diagnostics and treatments.  It is well known that 
influenza viruses have several surface proteins that are good targets for therapeutics.  The first 
class of anti-viral is target on M2 proteins.  However, this class of anti-viral has rendered 
inadequacy in recent years as the viruses mutate and have shown 100% resistance for both 
influenza A and B viruses.  The second generation of anti-viral drug is NA inhibitor.  As a result 
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of overused of Oseltamivir, several strains has shown resistance.  Thus, there is still a strong need 
to find new NA inhibitors. 
Early detection and surveillances of influenza viruses are critical for stopping the 
transmission of influenza.  However, the current detection methods suffer from poor sensitivities, 
low accuracy, and high turnaround period.  Cell culture is highly selective and sensitive, but suffers 
from long turn-around time (4-7 days). PCR is also highly sensitive and selective, but requires 
well-trained personnel. Antibody based detection is highly selective but suffers from low sensitive. 
Thus, there is still a high demand to develop new diagnostics method. 
2.2  Experiment Design 
We recently developed an electrochemical assay to detect influenza viruses using a glucose 
bearing substrate (Figure 2-8)35. Briefly, the neuraminidase (NA) enzyme, present in high 
abundance on the surface of influenza viruses36, cleaves this substrate to release glucose. Glucose 
is oxidized to gluconolactone and hydrogen peroxide by glucose oxidase present in the strips. 
Hydrogen peroxide can oxidize Prussian white to Prussian blue, the latter is reduced to Prussian 
white and generate one electron in the electrode. This electron can be measured amperometrically 
using a glucose meter or a portable potentiostat (Figure 2-9). Glucose meters also meet the 
ASSURED criteria and are used by millions worldwide and are increasingly being used to detect 
a variety of non-glucose targets37,38,39,40,41,17. In our previous report, we used SG1 (Figure 2-8) to 
detect 19 unique influenza strains in 1 hour. However, SG1 is cleaved by NA from any source, 
human, bacterial or viral, which makes differentiation between influenza virus and other pathogens 
problematic unless an additional step of using antiviral drugs is included. Additionally, time to 
results must be less than 15 minutes because patients cannot wait for 1h if this assay is going to be 
used in a clinical setting. 
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Figure 2-8 Electrochemical detection of influenza viruses. 
 
Figure 2-9 Workflow of the electrochemical assay. 
Herein, we have designed and synthesized an influenza specific substrate 4,7di- 
OMeSα2,3/6Gal (4,7di-OMe N-acetylneuraminic acid attached to the 3 or 6 position of galactose), 
and developed an assay that uses a portable potentiostat and commercial Accu-Chek strips. We 
demonstrated that this assay detects the influenza virus with high specificity within 15 minutes. 
Influenza NA, not bacterial NA, cleaved 4,7di-OMeSα2,3/6Gal to release galactose. In contrast, 
viral and bacterial NA both cleaved the natural substrate Sα2,3/6Gal (N-acetylneuraminic acid 
attached to the 3 or 6 position of galactose). The released galactose was detected amperometrically 
using a handheld potentiostat and dehydrogenase bearing glucose test strips. The specificity for 
influenza was confirmed using different influenza strains and respiratory pathogens such as 
Streptococcus pneumoniae and Haemophilus influenzae; bacteria do not cleave 4,7di-
OMeSα2,3/6Gal. The assay was also used to detect co-infections caused by influenza virus and 
Streptococcus pneumoniae. Viral drug susceptibility and testing with human clinical samples was 
25 
successful within 15 minutes, indicating that this assay could be used to rapidly detect influenza 
viruses at primary care or resource poor settings using ubiquitous glucose meters42. 
2.3 Results and discussions 
To develop highly specific substrates for influenza viral NA, we introduced a larger 
methoxy group at the 4 and 7 positions of N-acetyl neuraminic acid (sialic acid). We reasoned that 
the binding pocket of influenza NA can accommodate a larger group at the 4 and 7 positions of 
sialic acid. Indeed, X-ray structures (Figure 2-10) and functional assays from Zanamivir and 
Oseltamivir have confirmed that bacterial not human NA possess a smaller binding pocket and 
cannot accommodate larger groups43,31,44,45,46.  
 
Figure 2-10 Space filling model of active site of NAs with sialic acid derivatives as stick 
model. Left. X-ray structure of S. pneumoniae NanA with zanavimir (PDB: 2YA7). Right. X-ray 
structure of influenza NA with 4-guanidino-Neu5Ac2en (PDB: 1NNC). Note the smaller pocket of 
the bacterial NA, which can be exploited to develop influenza specific compounds. Structures were 
downloaded from protein database bank (PDB) and PyMOL (www.pymol.org) was used to create 
the models. 
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Several groups have exploited the unique nature of the virus active site to develop highly 
specific NA inhibitors that have amine/guanidine groups at the 4 position of sialic acid31,47,48. The 
amine or guanidine at the 4 position of sialic acid interacts with Glu119 and Glu227 present in the 
binding pocket of influenza NA. The same unique feature of the active site of influenza NA has 
been used to develop specific substrates for influenza virus49,50,51. Recently, Bennett and coworkers 
demonstrated that NA from virus or bacteria can accommodate a variety of groups at the 4 position 
of sialic acid, each molecule possessing a range of cleavage efficiency52. As a first step towards 
the development of highly specific substrates for influenza, we chose to introduce a methoxy group 
at the 4 and 7 positions of sialic acid and coupled it to the 3 or 6 hydroxyl group of D-galactose to 
establish proof of concept that these modifications lead to exclusive selectivity. We chose D-
galactose instead of D-glucose for three reasons. (i) The Accu-Chek strips detect galactose and 
glucose since it uses a dehydrogenase enzyme53,54. In contrast, glucose meters that use glucose 
oxidase detect only glucose and not galactose. (ii) Glucose may be present in the nasal or throat 
swabs of some patients; diabetic patients have low levels of glucose in their nasal cavity due to 
paracellular leakage, active co-transport, and facilitated diffusion that may interfere with the 
readings. (iii) Sialic acid attached to galactose and not glucose, is the natural substrate for NAs 
and therefore, could lead to a better fit at the active site. 
The synthesis of (4,7di-OMe)S2,6Gal is depicted in Scheme 2-1. Our strategy was to 
introduce the methoxy groups to the 4 and 7 positions of sialic acid before coupling to a suitably 
protected D-galactose acceptor. To this end, we synthesized compound 2-1, which was obtained 
from sialic acid using previously reported procedures49,50. The chloride derivative, 2-1 was reacted 
with 4-methyl thiophenol to afford compound 2-2 in decent yield, and it serves as donor in latter 
glycosylation. 
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Scheme 2-1. The synthesis of (4,7di-OMe)Sα2,6Gal. 
The synthesis of acceptor 2-3 follows the previous report55, shown in Scheme 2-2. Briefly, 
D-galactose was converted into per-benzyl-D-galactopyranoside using NaH and BnBr. ZnCl2 in 
Ac2O-HOAc was used to selectively deprotect 6-benzyl group and protect with acetyl group to 
furnish benzyl 6-O-acetyl-2,3,4-tri-O-benzyl-D-galactopyranoside. After removing acetyl group 
by NaOMe in MeOH, the acceptor 2-3 was achieved. 
 
Scheme 2-2. The synthesis of acceptor 2-3. 
The reaction of donor 2-2 with the suitably protected D-galactose acceptors 2-3 and NIS 
as promoter gave the alpha isomers, 2-4 in tolerable yields. A negligible amount (<5%) of the beta 
isomer was observed, however, this isomer was separated using standard column chromatography. 
The alpha linkage was confirmed using NMR spectroscopy; the H3eq of the sialic acid component 
for the alpha isomer in the coupled product 2-4 resonates at 2.8 ppm in the 1H NMR and the C2 
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carbon of the sialic acid resonates at 99.0 ppm in the 13C NMR. Global deprotection using a 
standard one-pot three step procedure resulted in the desired compounds in near quantitative yield.  
For the synthesis of 3-naked galactose acceptor 2-10, D-galactose was converted into 
benzyl-D-galactopyranoside using sulfamic acid in benzyl alcohol. Selectively installing a 4-
methoxybenzyl (PMB) group on the 3 position was furnished using two steps procedure: reflux 
with Bu2SnO in MeOH and react with PMBCl in toluene. After per-benzylation and PMB 
deprotection using DDQ, the suitable acceptor 2-10 was achieved, as shown in Scheme 2-3. 
 
Scheme 2-3. The synthesis of acceptor. 
With the glycosyl donor and acceptor in hand, the same strategy was used to synthesize 
(4,7di-OMe) S2,3Gal. The synthesis is shown in Scheme 2-4. 
 
Scheme 2-4. The synthesis of (4,7di-OMe)Sα2,3Gal. 
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Naturally occurring sialosides, S2,3Gal and S2,6Gal, a portable potentiostat and Accu-
Chek test strips to detect galactose were purchased. We found that the minimum detectable 
concentration of galactose over background signal was 0.3 mM from the standard curve for 
different concentrations of galactose (Figure 2-11). Therefore, we used a substrate concentration 
of 0.3 mM in all of our studies. 
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Figure 2-11 Standard curve galactose concentration versus current using Acck-Chek 
Aviva strips.  
Next, we tested the ability of NAs to cleave the substrates before testing with pathogens. 
Influenza NAs are arranged into two groups based on their sequences with N1, N4, N5, N8 and 
N2, N3, N6, N7, N9 being part of groups 1 and 2, respectively56,57. We chose N1 and N2 as 
representatives of the two major groups. N1 from H5N1 (A/Anhui/1/2005) was incubated with 
S2,3Gal or S2,6Gal substrate and the current was measured using a potentiostat (Figure 2-12).  
A discernable signal was obtained in 1h corresponding to 60% of substrate cleavage, and 
the difference between the signal and background is shown in Figure 2-13. A signal can also be 
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obtained in 15 minutes (Figure 2-14). A similar result was obtained when N2 from influenza A, 
H3N2/Babol/36/2005, was used, although the intensity of the signal was slightly lower, 
presumably because the activity of the N2 strain is not as high as the N1 strain. When recombinant 
bacterial NAs (from Streptococcus pneumoniae, Salmonella typhimurium, Clostridium 
perfringens and Arthrobacter ureafaciens) were exposed to S2,3Gal or S2,6Gal, we found all 
four NAs cleave S2,3Gal with high efficiency; however, two of the NAs (Streptococcus 
pneumoniae and Salmonella typhimurium) cleave S2,6Gal at a negligible rate as they do not 
recognize S2,6Gal glycans well. Some of these NAs have been derived from pathogens present 
in the digestive tract; therefore, these glycans could potentially be used to detect those pathogens 
if NAs from these pathogens are excreted in appreciable amounts in the urine or stool. 
 
Figure 2-12 Image of the electrochemical system used in these studies. The strips are 
connected to a potentiostat, which is connected to a smartphone. Left: Accu-Chek Avivastrips. 
Middle: portable potentiostat. Right: smartphone. 
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Figure 2-13 Detection of NA using natural substrates. (1) H5N1 NA (A/Anhui/1/2005), (2) 
H3N2 NA (A/Babol/36/2005), (3) NA from Streptococcus pneumoniae specific for 2-3 linkages, 
(4) NA from Salmonella typhimurium specific for 2-3 linkages, (5) NA from Clostridium 
perfringens specific for 2-3, 2-6 and 2-8 linkages and (6) NA from Arthrobacter ureafaciens 
specific for 2-3, 2-6, 2-8 and 2-9 linkages. 50 U of different enzymes was incubated with 
natural substrates at 37 oC for 1h. The current was measured using Accu-Chek Aviva strips (Roche 
Diagnostics) with the 10 s average current recorded 5 s following substrate introduction at a 
working potential of -0.15 V. The y axis, , represents the difference in current before and after 
the addition of the substrate. All experiments were performed in triplicate independently on 
different days to demonstrate scientific rigor. 
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Figure 2-14 Detection of N1 using Sα2,3Gal. 50 U of A/Anhui/1/2005 H5N1 NA was 
incubated with Sα2,3Gal at 37oC. The current was measured at 15 min and 60 min. 
Next, we tested the ability of these six NAs, with (4,7di-OMe)S2,3Gal or (4,7di-
OMe)S2,6Gal. We found that N1 and N2 from the two different groups of influenza cleave these 
new derivatives specifically and NAs from bacteria do not cleave the glycans, demonstrating 
excellent specificity. The cleavage rate of the new derivatives is slower than S2,3Gal and 
S2,6Gal; this is to be expected as the new derivatives are not the natural substrate (Figure 2-15).  
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Figure 2-15 . Detection of NA using (4,7di-OMe)Sα2,3Gal or (4,7di-OMe)Sα2,6Gal. (1) 
H5N1 NA (A/Anhui/1/2005), (2) H3N2 NA (A/Babol/36/2005), (3) NA from Streptococcus 
pneumoniae specific for 2-3 linkages, (4) NA from Salmonella typhimurium specific for 2-3 
linkages, (5) NA from Clostridium perfringens specific for2-3, 2-6 and 2-8 linkages and (6) 
NA from Arthrobacter ureafaciens specific for 2-3, 2-6, 2-8 and 2-9 linkages. 50 U of 
different enzymes was incubated with natural substrates at 37 oC for 1h. The current was measured 
using Accu-Chek Aviva strips (Roche Diagnostics) with the 10 s average current recorded 5 s 
following substrate introduction at a working potential of -0.15 V. The y axis, , represents the 
difference in current before and after the addition of the substrate. All experiments were performed 
in triplicate independently on different days to demonstrate scientific rigor. 
Next, we tested the ability of virus and bacteria, not just the recombinant NAs because 
recombinant NAs are not the same as the natural NAs. While enzymes may work well under 
controlled conditions, the assay may not work with intact viruses and bacteria. Viral NAs are 
1 2 3 4 5 6
0
5
10
15
20

I/
 n
A
Samples
 (4,7di-OMe)S2,3Gal
 (4,7di-OMe)S2,6Gal
34 
embedded on the cell surface as a tetramer, whereas recombinant NAs from the manufacturer are 
present as a mixture of monomers, dimers and tetramers. Also, bacteria produce multiple NAs. For 
example, S. pneumoniae produces three types of NA, one of which is a trans-sialidase58. To this 
end, we cultured influenza viruses and S. pneumoniae and characterized them using plaque assays. 
Since S. pneumoniae has been reported to use NA as a virulence factor, we grew S. pneumonia in 
the presence of sialic acid as it has been demonstrated that the bacteria produce more NAs when 
sialic acid is added to the growth media59. It was gratifying to observe the viral strains, H1N1 
(A/Brisbane/59/2007) and H3N2 (A/Victoria/361/2011) cleave all four compounds extremely 
well; in contrast, the two strains of S. pneumoniae (serotype 1, ATCC 6301 and serotype 1, ATCC 
6305) cleave only the natural substrates, (Figure 2-16) and not (4,7di-OMe)S2,3Gal or (4,7di-
OMe)S2,6Gal.  
 
 
Figure 2-16 Detection of influenza and S. pneumoniae. Different substrate [(Sα2,3Gal: 
Sα2,6Gal; (4,7di-OMe)Sα2,3Gal or (4,7di-OMe)Sα2,6Gal)] was incubated with different 
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pathogens [H1N1 (A/Brisbane/59/2007); H3N2 (A/Victoria/361/2011); SP1 (serotype 1, ATCC 
6301) or SP2 (serotype 1, ATCC6305)] at 37 oC for 1 h. 
We also demonstrated that Haemophilus influenzae, another respiratory pathogen, does not 
cleave (4,7di-OMe)S2,3Gal (Figure 2-17). Thus, the new derivatives can be used to detect 
influenza virus specifically. The assay can also detect influenza B virus in addition to influenza A, 
but not influenza C (Figure 2-17), as influenza C virus does not possess sialic acid cleavage 
activity60,61. 
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Figure 2-17 Specificity towards Influenza B, C, and H. Influenzae in 15 min (Top) and 60 
min (Bottom). 50 µL of B/Memphis/20/96, C/Taylor/1233/1947, or H. Influenzae was incubated 
with Sα23Gal (8.8 μL, 2 mM) or (4,7di-OMe)Sα23Gal (8.8 μL, 2 mM) at 37oC. 
The next set of experiments was designed to monitor antiviral efficacy. We premixed a 
H3N2 strain (A/Victoria/361/2011) with the anti-viral drug, Zanamivir i.e. Relenza, before adding 
the natural substrate, S2,3Gal. Zanamivir was used because strains develop resistance to 
Oseltamivir more frequently than Zanamivir62; in 2009, the majority of circulating H1N1 strains 
were resistant to Oseltamivir63. Galactose was not released because Zanamivir blocks the action 
of viral NA. When we performed the same experiment with S. pneumoniae (serotype 1, ATCC 
6305) instead of influenza virus, we found that galactose was released because Zanamivir does not 
block the action of bacteria (Figure 2-18). Next, we mixed the same virus and bacteria to simulate 
co-infections, followed by addition of Zanamivir and subsequent incubation of S2,3Gal. We 
found that galactose was released because the antiviral does not block the action of bacteria, 
however, the signal is lower indicating that the antiviral drug targeted influenza and not the 
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bacterium. Taken together, this assay can be used to detect influenza viruses and monitor treatment 
efficacy.  
 
Figure 2-18 Monitoring antiviral efficacy. 10 ng of Zanamivir was premixed with different 
pathogens [(H3N2 A/Victoria/361/2011, VZ), SP2 (serotype 1, ATCC 6305, SZ), or H3N2 
A/Victoria/361/2011 and SP2 (VSZ)] for 30 min before the addition of Sα2,3Gal. Also shown is 
data obtained without the addition of Zanamivir to the pathogens [(H3N2 A/Victoria/361/2011, 
V), SP2 (serotype 1, ATCC 6305, SP2), or A/Victoria/361/2011 and SP2 (VS)]. 
An added feature of this assay is that it can also be potentially used to detect co-infections 
caused by bacteria that overexpress NA as a virulence factor by using the natural and the modified 
substrate. For example, S. pneumoniae produces increased amounts of bacterial NA as a virulence 
factor during the infection process64. It has been shown that the cleavage of the terminal sialic acid 
on host cells exposes the underlying glycans, GalNAc1-4Gal, which serve as receptors for 
opportunistic pathogens to increase adhesion65 and the advancement of S. pneumoniae into the 
middle ear leading to otitis media in a chinchilla model66,67. Increase/decrease in the activity of 
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influenza NA and bacterial NA can be measured as a function of time to follow the infection 
process using ubiquitous glucose meters. This becomes important from a clinical standpoint, as 
the treatment regimen for influenza virus and bacterial infections are different; physicians typically 
treat bacterial infections with antibiotics and influenza virus with antivirals. 
The next set of experiments were designed to study the matrix effects. Since there is a 
plethora of natural flora in the nasal cavity, we were concerned that the human clinical samples 
may either have galactose in them and/or endogenous enzymes may cleave the substrate resulting 
in false positive result. To this end, we obtained nasal swabs from human volunteers who did not 
show any signs of influenza and clinical samples from patients who exhibited influenza like 
symptoms, but did not have influenza as determined by qRT-PCR. First, we tested nasal swabs in 
buffer and found minimal background (HV1, Figure 2-19). Spiking the sample with substrate 
(HV1+Sub) or H1N1 A/Brisbane/59/2007 (HV1+V) resulted in no appreciable signal. The 
HV1+Sub result indicates that there is nothing in the sample that cleaves the substrate and the 
HV1+V result indicates there is no endogenous compound that can be cleaved by the virus to 
release galactose. A signal was observed only when the sample with spiked with both virus and 
substrate (HV1+Sub+V).  
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Figure 2-19 Detection of spiked H1N1 influenza virus in human samples.  A nasal swab 
from human volunteer 1 was incubated with PBS only (HV1), substrate (HV1+Sub), virus 
(HV1+V), or substrate + virus (HV1+Sub+V) at 37 oC for 15 min. The y axis, I, represents the 
current. The current was measured using Accu-Chek Aviva strips (Roche Diagnostics) with the 10 
s average current recorded 5 s following substrate introduction at a working potential of -0.15 V. 
All experiments were performed in triplicate independently on different days to demonstrate 
scientific rigor. 
We repeated these experiments with multiple samples that include buffer (PBS), two 
healthy human volunteer samples and three clinical samples from patients who did not have 
influenza (Figure 2-20). The spiked virus was detected in all samples, indicating that this assay 
could be used in a clinical setting. Most importantly, measuring the signal before and after the 
introduction of the substrate eliminates any background signal due to endogenous galactose or 
glucose or other interferences.  
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Figure 2-20 Detection of human samples. (4,7di-OMe)S2,3Gal was incubated with 
different matrices such as PBS, HV1, HV2, A, B, or C at 37 oC for 15min. PBS is buffer, and HV1 
and HV2 are nasal swabs from human volunteers. A, B and C are samples from patients who did 
not have influenza as determined by qRT-PCR. The current was measured using Accu-Chek Aviva 
strips (Roche Diagnostics) with the 10 s average current recorded 5 s following substrate 
introduction at a working potential of -0.15 V. The y axis, DI, represents the difference in current 
before and after the addition of the substrate. All experiments were performed in triplicate 
independently on different days to demonstrate scientific rigor. 
The limit of detection of this assay for H1N1 A/Brisbane/59/2007 and H3N2 
A/Victoria/361/2011 was determined to be 102 pfu per sample and S. pneumoniae (serotype 1, 
ATCC 6305) was 102 cfu per sample in 15 minutes (Figure 2-21,2-22). This is clinically significant 
as patients entering the clinic typically carry viral particles in their nose or throat68,69. With longer 
incubation times, the limit of detection is 102 pfu per sample as this is an enzyme based system 
(Figure 2.23). 
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Figure 2-21 Limit of detection. Top: The limit of detection of this method with (4,7di-
OMe)Sα23Gal and A/Brisbane/59/2007 was 102 pfu in 15 min.  Bottom: The limit of detection of 
this method with (4,7di-OMe)Sα23Gal and A/Victoria/361/2011 was 102 pfu in clinical sample B 
at 15 min. The current was measured using Accu-Chek Aviva strips.  
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Figure 2-22 Limit of detection. The limit of detection of this method with Sα23Gal and S. 
pneumoniae (serotype 1, ATCC 6305) was 102 cfu in 15 min. The current was measured using 
Accu-Chek Aviva strips. 
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Figure 2-23 Time course study. Time curve of different concentration of virus for 24h (top) 
and 6h (bottom). 50 µL of A/Victoria/361/2011 (101~104 pfu) was incubated with Sα23Gal (8.8 
μL, 2 mM) at 37 oC. The current was measured using Accu-Chek Aviva strips at 15 min, 1 h, 2 h, 
3 h, 4 h, 5 h, 6 h, and 24 h. 
2.4 Conclusions 
We have developed a novel assay that can detect clinically relevant influenza viruses with 
high specificity within 15 minutes, which makes this technique highly relevant for a point of care 
setting. While we used a portable potentiostat and commercially available test strips as part of our 
protocol, glucose meters could also be used. The advantages of this assay are that it meets the 
ASSURED criteria and uses existing technology for a new purpose i.e. a glucose meter to detect 
and differentiate these pathogens. Antiviral susceptibility can also be measured rapidly. An added 
feature of this assay is that disease progression and response to therapy can be tracked using the 
natural substrate and the new derivatives to monitor increased/decreased activity of viral and 
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bacterial NAs. For example, other pathogens present in the respiratory tract can cause secondary 
infections after the initial attack by influenza has diminished. S. pneumoniae, a pathogen that 
already exists in the respiratory tract can cause secondary infections particularly in patients with 
weak (e.g. children and senior citizens) or compromised (e.g. patients with human immunode 
deficiency virus, tuberculosis or organ transplants) immune systems70. Multiple studies have 
demonstrated that the initial influenza infection leads to subsequent bacterial infection, typically 
caused by S. pneumoniae; this combination “one-two punch” is lethal resulting in intensive care 
hospitalizations and death, especially in conjunction with pandemic influenza 
strains71,72,73,74,75,76,77. We anticipate that this concept will be applied to the detection of other 
infectious agents or other human disorders. 
2.5 Experimental section 
2.5.1 Materials 
2-3 NA S (S. pneumoniae), 2-3 NA (Salmonella typhimurium), 2-3,6,8 NA 
(Clostridium perfringens) and 2-3,6,8,9 NA A (Arthrobacter ureafaciens) were purchased from 
New England Biolabs, Ipswich, MA. H5N1 (A/Anhui/1/2005) and H3N2 (A/ Babol/36/2005) 
neuraminidase were purchased from Sino Biological Inc., Beijing, China. S. pneumoniae ATCC 
6301 and S. pneumoniae ATCC 6305 were purchased from American Type Culture Collection 
(ATCC). S2,6Gal and S2,3Gal were purchased from Carbosynth Limited, Berkshire, UK. 
Accu-Chek Aviva strips were purchased from Amazon, Seattle, WA. Influenza strains were 
obtained from BEI resources, NIAID. All experiments with human clinical samples were approved 
by Georgia State University Institutional Review Board. 
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2.5.2 Bacterial growth 
Briefly, S. pneumoniae ATCC 6301 and S. pneumoniae ATCC 6305 were inoculated in 
Brain Heart Infusion (BHI) broth augmented with 0.16 g L-1 of sialic acid to enhance NA 
production by the bacteria. The bacterial concentration was determined to be 106 CFU mL-1 using 
filtration and the colony count method. Bacteria was lysed using the method described by 
Giacomini et al78. To 100 mL of bacterial samples, 0.01% SDS and 20 mL of chloroform were 
added. The samples were vigorously vortexed for 30 s and incubated at 28oC for 5 min to allow 
bacterial lysis. 
2.5.3 Detection of different substrates 
50 U of the neuraminidase was mixed with 1 µL of GlycoBuffer (10X, pH 5.5) and 1.5 µL 
of substrate (2 mM). DI H2O was added to bring the volume to 10 µL. The mixture was incubated 
at 37 oC for 1 h. 1.5 µL of this solution was used to measure the current using Accu-Chek Aviva 
strips for an average of 10 s recorded 5 s following substrate introduction at a working potential 
of -0.15 V. 
2.5.4 Detection of influenza virus and S. pneumoniae 
50 µL of A/Brisbane/59/2007 (1.25×107 pfu mL-1), A/Victoria/ 361/2011 (3.5×106 pfu mL-
1), S. pneumoniae (serotype 1, ATCC 6301, 106 CFU mL-1), or S. pneumoniae (serotype 1, ATCC 
6305, 106 CFU mL-1) was mixed with 8.8 µL of substrate (2 mM). The resulting mixture was 
incubated at 37 oC for 1 h. 1.5 µL of this solution was used to measure the current using Accu-
Chek Aviva strips for an average of 10 s recorded 5 s following substrate introduction at a working 
potential of -0.15 V as described previously79. 
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2.5.5 Antiviral efficacy study 
10 ng of Zanamivir was premixed with 50 µL of H3N2 A/Victoria/ 361/2011 (3.5×106 pfu 
mL-1), S. pneumoniae (serotype 1, ATCC 6305, 106 CFU mL-1), or a mixture of virus and bacteria 
for 30 min at oC. 
1.5 µL of this solution was used to measure the current using Accu-Chek Aviva strips for an 
average of 10 s recorded 5 s following substrate introduction at a working potential of -0.15 V. 
2.5.6 Detection of clinical samples 
25 µL of PBS, HV1, HV2, A, B, or C was mixed with 25 µL of virus (H1N1 
A/Brisbane/59/2007, 1.25×107 pfu mL-1), followed by the addition of 8.8 µL of 2 mM solution of 
(4,7di-OMe)S2,3Gal in PBS. The resulting mixture was incubated at 37 oC for 15min. 1.5 µL of 
this solution was used to measure the current using Accu- Chek Aviva strips for an average of 10 
s recorded 5 s following substrate introduction at a working potential of -0.15 V. 
2.5.7 Chemical synthesis and characterization: 
General: 
Glycosylation reactions were performed under argon with solvents dried using a solvent 
purification system Innovative Technology. All chemical reagents were of analytical grade, used 
as supplied without further purification unless indicated. The acidic ion exchange resin used was 
Amberlite® IR 120 (H+) resin. Column chromatography was performed using silica gel (230-400 
mesh). Analytical thin layer chromatography (TLC) was performed on silica gel 230-400 mesh 
(Sicicycle). Plates were visualized under UV light, and/or by staining with acidic CeH8Mo3N2O12 
followed by heating. 1H and 13C NMR spectra were recorded on Bruker 400MHz spectrometer. 
Chemical shifts are reported in δ (ppm) units using residual13C and 1H signals from deuterated 
solvents as references. Spectra were analyzed with MestReNova® (Mestrelab Research). 
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Electrospray ionization mass spectra were recorded on a Micromass Q \T 2 (Waters) and data were 
analyzed with MassLynx® 4.0 (Waters) software. Reported yields refer to spectroscopically and 
chromatographically pure compounds that were dried under high vacuum (10–2 mbar) before 
analytical characterization, unless otherwise specified. 
Abbreviations: Ethyl acetate, EtOAc; Dichloromethane, DCM; Trific acid, TfOH; N-
Iodosuccinimide, NIS; Sodium methoxide, NaOMe; Methanol, MeOH; Palladium hydroxide, 
Pd(OH)2; Ethanol, EtOH; Sodium hydroxide, NaOH; Triethyl amine, NEt3; Thin layer 
chromatography, TLC. Sodium thiosulfate, Na2S2O3; Sodium sulfate, Na2SO4. 
Benzyl 2,3,4,5-tetra-O-benzyl-α/β-D-galactopyranoside (2-5) 
 
To a suspension of D-galactose (4.5 g, 25 mmol) in DMF, NaH (10.0 g, 250 mmol) was 
added portion by portion. The resulting solution was stirred at 0oC for 30 min, followed by the 
addition of benzyl bromide (17.8 mL, 150 mmol) dropwise. The reaction mixture was stirred 
overnight at rt. The reaction was quenched by slowly adding MeOH. DMF was removed under 
reduced pressure. The residue was subjected to flash chromatography eluting with 
Hexane:EtOAC=5:95 yielded a white solid (12.0 g, 76%).  
Benzyl 6-O-acetyl-2,3,4-tri-O-benzyl-α/β-D-galactopyranoside (2-6) 
 
To a mixture of ZnCl2 (4.32 g, 31.7 mmol) in HOAc-Ac2O (1:5, 30 mL) at 0 
oC, compound 
2-5 (4.0g, 6.3 mmol) in HOAc-Ac2O (1:5, 24 mL) was added dropwise. The reaction mixture was 
stirred at rt until the starting material was consumed checking by TLC. Then 180 mL of ice water 
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was added, the mixture was extracted with EtOAc twice. The combined organic layer was washed 
with saturated NaHCO3 and dried over Na2SO4, and concentrated under reduced pressure. The 
residue was subjected to flash column eluting with Hexane:EtOAc=1:9 yielded a white solid (2.96 
g, 80%). 
Benzyl 2,3,4-tri-O-benzyl-α-D-galactopyranoside (2-3) 
 
To a solution of compound 2-6 (2.96 g, 5.07 mmol) in MeOH, 30% NaOMe in MeOH was 
added. The reaction mixture was stirred at rt for 2h. The solution was neutralized with Amberlite® 
IR 120 (H+) resin, filtered and concentrated to dry. The residue was subjected to flash column 
eluting with Hexane:EtOAc=15:85 to yielded α-isomer (1.51 g, 2.79 mmol, 55%) as a white solid. 
5-acetamido-8,9-di-O-acetyl-4,7-di-O-methyl-3,5-dideoxy-D-glycero-α-D-galacto-2-
ulopyranosylonate-(2→6)-1,2,3,4-tetra-O-benzyl-α-D galactopyranoside (2-4) 
 
To the stirring solution of acceptor 2-3 (75 mg, 0.14 mmol) and donor 2-2 (50 mg, 0.092 
mmol) in anhydrous DCM under an argon atmosphere at -50oC, NIS (0.052g, 0.23 mmol) was 
added followed by the addition of TfOH (0.014g, 0.092 mmol, 10% in anhydrous DCM). The 
reaction mixture was stirred at -50oC until the donor was consumed as determined by TLC. Et3N 
(0.5 mL) was added to quench the reaction and warmed to rt. The reaction mixture was diluted 
with DCM, washed with saturated Na2S2O3, dried over Na2SO4 and concentrated under reduced 
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pressure. The residue was subjected to flash silica gel column chromatography eluting with 
hexane:EtOAc (90:10) to afford compound 4 as a white solid (0.035g, 0.036 mmol, 40%).1H NMR 
(400 MHz, CDCl3): δ 7.39-7.23 (m, 20H), 5.38-5.35 (m, 1H), 5.25-5.22 (m, 1H), 4.90 (d, J=4.0 
Hz, 1H), 4.76-4.70 (m, 3H), 4.66-4.63 (m, 1H), 4.63-4.60 (m, 1H), 4.56-4.49 (m, 2H), 4.45-4.43 
(m, 3H), 4.20 (dd, J=4.0 Hz, 12.0 Hz, 1H), 4.05-3.98 (m, 4H), 3.69 (s, 3H), 3.64-3.62 (m, 2H), 
3.55 (d, J = 4.0 Hz, 1H), 3.49 (s, 3H), 3.38 (s, 1H), 3.32 (s, 3H), 2.74 (dd, J=8.0Hz, 1H), 2.19 (s, 
3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.75-1.69 (m, 1H). 13C NMR (100 MHz, CDCl3): δ 170.5, 170.3, 
169.8, 168.4, 138.7, 138.4, 137.7, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 127.8, 127.8, 127.6. 
127.5, 127.2, 99.0, 97.7, 84.1, 80.4, 79.6, 73.2, 72.5, 72.4, 72.2, 70.9, 68.2, 63.2, 62.8, 60.9, 55.7, 
52.4, 50.3, 36.7, 29.7, 23.7, 22.7, 21.1, 20.8. HRMS (ESI): Calculated for C52H63NO16Na [M+Na] 
980.4045; Found 980.4043. 
5-acetamido-4,7-di-O-methyl-3,5-dideoxy-D-glycero-α-D-galacto-2-
ulopyranosylonate-(2→6)-α, β-D-galactopyranoside ((4,7di-OMe)Sα2,6Gal) 
 
Compound 2-4 (0.035g, 0.036 mmol) was dissolved in MeOH and treated with 30% 
NaOMe in MeOH and stirred at rt for 1 h. The solution was neutralized with Amberlite® IR 120 
(H+) resin, filtered and concentrated to dry. The dried compound was further treated with 
Pd(OH)2/C in absolute EtOH and stirred at rt for 12h under H2 at 1 atm. After completion of 
reaction as monitored by TLC, the reaction mixture was filtered through celite pad, washed with 
EtOH and the combined solvent was concentrated to dry. The residue was then treated with 0.05 
N NaOH in H2O and stirred at rt for 2h. After completion of reaction, as monitored by TLC, the 
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mixture was neutralized using Amberlite® IR 120 (H+) resin, filtered, concentrated and subjected 
to P-2 column to afford compound (4,7di-OMe)Sα2,6Gal (0.017g, 0.034 mmol, 94% over three 
steps).1H NMR (400 MHz, D2O): 5.15 (d, J=4.0 Hz, 0.6H, H1α), 4.47 (d, J=8.0 Hz, 0.4H, H1β), 
4.13-4.08(m, 1H), 3.89-3.77 (m, 5H), 3.76-3.74 (m, 1H), 3.71-3.52(m, 5H)3.41-3.37 (m, 
1H), 3.35 (s, 3H), 3.30 (s, 3H), 2.78-2.72 (dd, 1H, J=4.0, 12.0 Hz), 1.96 (s, 3H), 1.64-1.57 
(m, 1H). 13C NMR (100 MHz, D2O): 174.2, 171.3, 99.3, 96.4, 92.1, 78.0, 77.3, 73.3, 72.8, 72.6, 
71.7, 70.8, 68.2, 62.4, 60.3, 56.7, 49.9, 36.0, 22.2. HRMS (ESI): Calculated for C19H33NO14Na 
[M+Na] 522.1799; Found 522.1786. 
Benzyl α/β-D-galactopyranoside (2-7) 
 
To a suspension of D-galactose (4.5 g, 25 mmol) in benzyl alcohol (10 mL) was added 
sulfamic acid (500 mg, 5.0 mmol) at rt. The reaction mixture was stirred at 80oC for 5 h. After 
completion of the reaction, the solvent was removed under reduced pressure. The residue as used 
for the next reaction without further purification. 
Benzyl 3-O-(4-methoxybenzyl)-α/β-D-galactopyranoside (2-8) 
 
Compound 2-7 (1.62 g, 6.0 mmol) was dissolved in 30 mL of anhydrous MeOH and 
Bu2SnO (2.24 g, 9.0 mmol) was added. The reaction mixture was reflux for 6 h until the solution 
became clear. The solvent was removed under reduced pressure. The residue was dissolved in 
anhydrous toluene and followed by the addition of PMBCl (1.2 mL, 9.0 mmol) and TBAB (0.97 
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g, 3.0 mmol). The reaction was stirred overnight at 60 oC, concentrated in vacuo and purified by 
column eluting with Hexane:EtOAc (1:2) to obtain compound as a white solid (1.78 g, 76%). 
Benzyl 2,4,6-tri-O-benzyl-3-O-(4-methoxybenzyl)-α/β-D-galactopyranoside (2-9) 
 
To a solution of compound 2-8 (1.78 g, 4.56 mmol) in anhydrous DMF at 0 oC, NaH (0.72 
g, 18 mmol) was added. The reaction mixture was stirred at 0 oC for 30 min, followed by the 
addition of benzyl bromide (2.14 mL, 18 mmol) dropwise. The reaction mixture was stirred at rt 
for 6 h and dilute with H2O. The aqueous layer was extracted with EtOAc twice. The combined 
organic layer was washed with brine and dried over Na2SO4.  The solvent was removed in vacuo 
and purified by column eluting with Hexane:EtOAc (1:9) to afford the desired product as a white 
solid (2.42 g, 80%). 
Benzyl 2,4,6-tri-O-benzyl-α/β-D-galactopyranoside (2-10) 
 
To a solution of compound 2-9 (2.0 g, 3.03 mmol) in DCM, DDQ (1.03g, 4.54 mmol) was 
added. Then 1 mL of H2O was added to the reaction mixture. The reaction was stirred at rt until 
the starting material was consumed as determined by TLC. The reaction mixture was diluted with 
H2O and the aqueous layer was extracted with DCM. The combined organic layer was washed 
with saturated NaHCO3 and brine, dried over Na2SO4 and concentrated to dry. The residue was 
subjected to column eluting with Hexane:EtOAc (15:85) to furnish the desired compound (0.65 g, 
1.21 mmol) as a white solid. 
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5-acetamido-8,9-di-O-acetyl-4,7-di-O-methyl-3,5-dideoxy-D-glycero-α-D-galacto-2-
ulopyranosylonate-(2→3)-1,2,4,6-tetra-O-benzyl-α-D-galactopyranoside (2-11) 
 
To the stirring solution of acceptor 2-10 (75 mg, 0.14 mmol) and donor 2-2 (50 mg, 0.092 
mmol) in anhydrous DCM under an argon atmosphere at -50oC, NIS (0.052g, 0.23 mmol) was 
added followed by the addition of TfOH (0.014g, 0.092 mmol, 10% in anhydrous DCM). The 
reaction mixture was stirred at -50oC until the donor was consumed as determined by TLC. Et3N 
(0.5 mL) was added to quench the reaction and warmed to rt. The reaction mixture was diluted 
with DCM, washed with saturated Na2S2O3, dried over Na2SO4 and concentrated under reduced 
pressure. The residue was subjected to flash silica gel column chromatography eluting with 
hexane:EtOAc (90:10) to afford compound 4 as a white solid (0.033g, 0.034 mmol, 37%). 1H NMR 
(400 MHz, CDCl3): 7.37-7.26 (m, 20H), 5.39-5.36 (m, 1H). 5.21 (d, J=8.0 Hz, 1H), 5.16-5.12 (s, 
1H), 4.78 (d, J=12.0 Hz, 1H), 4.74 (d, J=12.0 Hz, 1H), 4.65 (d, J=12.0 Hz, 1H), 4.54-4.40 (m, 4H), 
4.35 (d, J=12.0 Hz, 1H), 4.21 (br, 2H), 4.15-4.01 (m, 4H), 3.98-3.91 (m, 1H), 3.37 (s, 3H), 3.58-
3.54 (br, 2H), 3.50 (s, 3H), 3.38 (s,1H), 3.32 (s, 3H), 2.75 (dd, J=4.0 Hz, 12.0 Hz, 1H), 2.12 (s, 
3H), 2.05 (s, 6H), 1.76-1.70 (m, 1H). 13C NMR (100 MHz, CDCl3): 171.2, 170.3, 170.2, 168.2, 
138.3, 138.0, 137.9, 137.8, 131.6, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 127.6, 
127.5, 104.8, 99.1, 88.6, 82.5, 80.1, 75.3, 73.3, 72.8, 72.1, 71.7, 70.5, 68.6, 63.3, 62.9, 61.0, 60.4, 
55.8, 52.5, 50.2, 36.7, 29.7, 23.8, 21.1, 21.0, 20.8. HRMS (ESI): Calculated for C52H63NO16Na 
[M+Na] 980.4045; Found 980.4048. 
5-acetamido-4,7-di-O-methyl-3,5-dideoxy-D-glycero-α-D-galacto-2- 
ulopyranosylonate-(2→3)-α, β-D-galactopyranoside ((4,7di-OMe)Sα2,3Gal) 
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Compound 2-11 (33 mg, 0.034 mmol) was dissolved in MeOH and treated with 30% 
NaOMe in MeOH and stirred at rt for 1 h. The solution was neutralized with Amberlite® IR 120 
(H+) resin, filtered and concentrated to dry. The dried compound was further treated with 
Pd(OH)2/C in absolute EtOH and stirred at rt for 12h under H2 at 1 atm. After completion of 
reaction as monitored by TLC, the reaction mixture was filtered through celite pad, washed with 
EtOH and the combined solvent was concentrated to dry. The residue was then treated with 0.05 
N NaOH in H2O and stirred at rt for 2h. After completion of reaction, as monitored by TLC, the 
mixture was neutralized using Amberlite® IR 120 (H+) resin, filtered, concentrated and subjected 
to P-2 column to afford compound (4,7di-OMe)Sα2,3Gal (15 mg, 0.035 mmol, 88% over three 
steps). 1H NMR (400 MHz, D2O): 5.14 (d, J=4.0 Hz, 0.4H, H1α). 4.47 (d, J=8.0 Hz, 0.4H, H1β). 
3.99-3.96 (m, 1H). 3.89-3.69 (m, 7H), 3.61-3.57 (m, 5H), 3.35 (s, 3H), 3.30 (s, 3H), 2.78-2.72 (m, 
1H), 1.96 (s, 3H), 1.67-1.57 (m, 1H). 13C NMR (100 MHz, D2O): 174.1, 173.6, 100.1, 96.3, 92.2, 
78.4, 77.9, 76.0, 74.9, 72.7, 71.2, 70.2, 67.7, 62.2, 61.0, 60.0, 56.7, 49.8, 36.4, 22.2. HRMS (ESI): 
Calculated for C19H33NO14Na [M+Na] 522.1799; Found 522.1788. 
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3 CHAPTER 3.  INDIRECT DETECTION OF GLYCOSIDASE USING 
AMPEROMETRY 
3.1 Introduction 
Glycosidases are important enzymes that hydrolyze oligosaccharides and the glycan 
components of glycoproteins and glycolipids (Figure 3-1). These ubiquitous enzymes catalyze the 
cleavage of glycoside bonds and have been widely used in a number of industrial applications, 
such as food processing and wood processing for paper and pulp products80,81,82. They have also 
been used as catalysts to form glycoside bonds via transglycosylation or by reverse hydrolysis83.  
 
Figure 3-1 The function of glycosidases. 
Based on different functions, glycosidase can be categorized into endo-glycosidases, exo-
glycosidases, glycosynthases, reverse hydrolysis etc. Glycosidase can also be divided by catalytic 
mechanism: retaining glycosidases, inverting glycosidases and β-N-acetylhexoaminidases. The 
details about these different categories are shown below. 
3.1.1 Retaining glycosidases 
Retaining glycosidases (Figure 3-2) act through a double substituent mechanism (twice of 
SN2 reaction at the anomeric center). In the first step, the first carboxylate serves as a nucleophile 
to attack the anomeric center and form a covalent glycosyl-enzyme intermediate. In the second 
step, water or another acceptor serves as a nucleophile and attacks the anomeric center again to 
hydrolyzes the glycosyl-enzyme intermediate yielding a new glycosidic linkage.  
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Figure 3-2 Retaining glycosidases mechanism 
3.1.2 Inverting glycosidases  
Inverting glycosidases (Figure 3-3) undergoes a single step nucleophilic substituent 
attacking by water molecule. 
 
Figure 3-3 Inverting Glycosidases mechanism. 
3.1.3 3.1.3 β-N-acetylhexosaminidases 
-N-acetylhexosaminidases (Figure 3-4) works similar with retaining glycosidases, both 
through two times of substituent. The only difference is that acetylamino group acts as neighboring 
group participation and form an oxazoline intermediate. This process is also called substrate-
assisted catalysis.  
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Figure 3-4 -N-acetylhexosaminidases hydrolysis mechanism. 
3.2 Detection of glycosidases 
Numerous bacteria, fungi, parasites, and viruses express glycosidases to degrade glyco 
oligo/ polymers. Glycosidases are also excreted in bodily fluids. Detection of glycosidases is often 
used to report the presence/ absence of a pathogen or indicate disease states. For example, detection 
of coliforms in drinking water, recreational pools, and bodies of water is performed by testing for 
β-galactosidase and/ or β-glucuronidase84,85. In a different study, α-mannosidase has been used as 
a biomarker to identify Chlamydia trachomatis infections86. A comprehensive list of glycosidases 
used to detect specific pathogens is provided in a recent report87. 
Several colorimetric, fluorogenic and chemiluminescence substrates for glycosidases are 
commercially available for the rapid detection of pathogens and to report human disorders. 
Cleavage of the substrate releases the reporter molecule and the enzyme activity can be accurately 
measured using a fluorescence detector. For example, β-galactosidase cleaves 5- bromo-4-chloro-
3-indolyl-α-D-galactopyranoside to release galactose and 5-bromo-4-chloro-3-hydroxyindole88. 
The latter spontaneously dimerizes and is oxidized into 5,5′-dibromo-4,4′- dichloro-indigo, an 
intensely blue insoluble product89 (Figure 3-5). Since X-Gal itself is colorless, the presence and 
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concentration of the blue-colored product can be used as a test for the presence of an active β-
galactosidase. In a specific application, X-gal was used to differentiate endogenous β- 
galactosidase activity from lacZ gene expression.  
 
Figure 3-5 Colorimetric detection of glycosidase. 
We were interested in developing an electrochemical assay that would use existing, 
ubiquitous glucose meters for the rapid detection of glycosidase activity. Unlike colorimetric 
methods that rely on a color change, which could be subject to misinterpretation especially when 
opaque and turbid samples are used, amperometric approaches are not subject to visual change in 
color. The use of glucose meters is very attractive for point of care diagnostics because glucose 
meters meets the ASSURED (Affordable, Sensitive, Selective, User-friendly, Rapid and robust, 
Equipment free and Deliverable to endusers) guidelines, established by the World Health 
Organization4. Glucose meters are very affordable as the meters are a one time cost and the 
disposable strips are inexpensive. The system is highly selective as it uses glucose oxidase or 
dehydrogenase and measurements are performed using microliters of blood. Most personal glucose 
instruments are quite sensitive, with an operating detection range between 50 and 180 mg/dL and 
meet ISO accuracy standards, which requires accuracy to be within 15% of the actual number. The 
more recent meters and disposable strips, such as StatStrip glucose meters produced by Nova 
Biomedical, are extremely accurate and have been approved by FDA for detecting glucose in 
neonatal and pediatric patients90,91,92. In terms of ease of use, the test kits are very easy to use and 
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are being used by millions worldwide. The tests are also very rapid with results obtained within 
seconds and the shelf life of most disposable strips is 6 months from the manufacturing date. 
Unlike PCRs, the device is equipment free and uses a battery as an electrical source, and the results 
can be downloaded onto a personal computer or mobile device. Finally, the glucose meter is 
portable and lightweight and has a small footprint making it readily deliverable to end-users. Taken 
together, the glucose meter represents a very important technological advance that has helped 
millions of patients to monitor their glucose and control complications related to diabetes mellitus. 
In this report, we have developed glycoside specific substrates that release glucose upon exposure 
to their respective glycosidases. 
3.3 Results and Discussions 
Our approach to the detection of glycosidases was to design and develop compounds that 
could release glucose upon action of enzymes. The released glucose can be measured directly using 
glucose meters (Figure 3-6).  
75
mg/ml
 
Figure 3-6 Electrochemical detection of glycosidase. 
The work flow of this assay is depicted in Figure 3-7. There are two components of the 
assay. In the first part, the sample is incubated with the substrate and glucose is released if the 
enzyme is present. The second part involves detection of glucose. Briefly, a drop of the sample is 
tested with screen printed electrodes impregnated with glucose oxidase and a mediator. In this 
study, we purchased screen printed electrodes with a three electrode configuration (CH 
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Instruments, Austin, TX). We deposited glucose oxidase and the mediator (Prussian blue) as 
described previously93,35. Glucose oxidase and the cofactor, FAD, present on the strip oxidizes 
glucose to gluconolactone and the cofactor gets reduced to FADH2. O2 oxidizes the FADH2 back 
to FAD and hydrogen peroxide (H2O2) is released. H2O2 oxidizes Prussian white to Prussian blue, 
which is converted back to Prussian white via electron gain at a low potential. The gain/loss of 
electrons is measured by a potentiostat or a glucose meter. If glucose is present in the sample, it 
will indicate presence of the enzyme, which can be directly correlated to a disease state or presence 
of the pathogen. This approach has been used to detect pathogens, nucleic acids, and 
enzymes40,37,38,94,95,96,97. Recently, we reported the detection of a library of unique influenza viruses 
using this approach35. Here, we report the design, synthesis of a panel of glycosidase specific 
substrates, and their amperometric detection using disposable test strips. 
 
Figure 3-7 Workflow of the assay depicts the two components: (i) production of glucose 
and (ii) detection of glucose. 
We synthesized glucose bearing substrates for five different glycosidases, namely, α-D-
mannosidase, β-D-galactosidase, β-Dglucuronidase, β-D-N-acetylglucosaminidase, and α-L-
fucosidase. The structures of the compounds for their respective enzymes are depicted in Table 3-
1. Since the enzymes are highly specific for their respective substrates, the negative control for a 
particular enzyme is a compound that is specific for a different enzyme. The synthesis of these 
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compounds were finished by our former postdocs, Dr. Gurale and Dr. Dhawane.  Briefly, a suitably 
protected donor bearing a good leaving group at the anomeric position was reacted with 4- 
hydroxyl benzaldehyde, followed by reduction of the aldehyde group to the corresponding alcohol, 
which was reacted with a suitably protected glucose derivative to yield the coupled product. We 
choose to introduce the benzyloxy spacer between the two monosaccharides as it provides a degree 
of flexibility for the enzyme to bind and cleave the glycoside bond. Removal of the protecting 
groups results in the desired product. As an example, the synthesis of the substrate for α-D-
mannosidase, (α-D-mannopyranosyloxy)-1-benzyloxy]-1-α/β-D-glucopyranoside is described. 
The known 2,3,4,6 tetra-acetate α-D mannose trichloroacetimidate donor98 and p-hydroxy 
benzaldehyde as an acceptor was dissolved in DCM and cooled to 0 °C. Addition of TMSOTf as 
the promoter resulted in exclusive α product in high yield. The aldehyde was reduced to the alcohol 
using sodium borohydride. This alcohol was reacted with 2,3,4,6-tetra-O-acetyl-α-D-
glucopyranoside trichloroacetimidate in the presence of TMSOTf as promoter to yield the 
predominantly β product (α/β in a 1:2 ratio) in high yields. Zemplén deprotection of the acetate 
groups resulted in the desired products, which was purified using size exclusion chromatography. 
The syntheses of the other derivatives were performed in a similar manner. For α-L-fucosidase, 
we synthesized an additional derivative, where we attached the glucose directly to α-L-fucose 
because the enzyme is not very active when a benzyloxy spacer is introduced as a spacer. 
The panel of compounds was tested with their respective enzymes for glucose release 
(Table 3-1). For these studies, the released glucose was measured amperometrically using a 
standard three electrode system as described previously. When α-mannosidase was introduced to 
1 mM of its substrate, (α-D-mannopyranosyloxy)-1-benzyloxy]-1-α/β-D-glucopyranoside, 
cleavage of the mannose occurred within minutes to yield the benzyloxy intermediate, which 
61 
degraded rapidly to release glucose and the quinone derivative. The resulting current at 60 min 
was around 
Table 3-1Detection of glycosidase measured by electrochemcial assay. 
 
81×10−8 A, which suggested that 75% of the reaction was completed in 1 h as complete cleavage 
should result in a value of 120×10−8 A. We note that one could measure released glucose 
continuously using a continuous glucose monitor, we choose to measure glucose after 1 h for our 
initial studies. A continuous glucose monitor would provide more information, similar to a HPLC-
PED (pulsed electrochemical detection); however, the cost and equipment needs of a continuous 
meter and/or HPLC instrument would negate the “affordable” and “equipment free” parts of the 
ASSURED guidelines99. We also note that, despite two monosaccharides mannose and glucose 
being released upon the action of the enzyme, we choose to detect glucose since glucose meters 
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are widely available, but detectors for mannose are unavailable. The negative control used for α- 
mannosidase was (α-D-glucuronic acid)-1-benzyloxy]-1-α/β-D-glucopyranoside and the value for 
this molecule was only ∼12×10−8 A. This value is not zero because the screen printed electrodes 
that we modified using glucose oxidase and the mediator produced a residual current when PBS 
buffer is used, which is ∼9 × 10−8 A. Glucose is released when the enzymes for the respective 
substrates are used. Glucose is not released when a different substrate is used (Table 1). The current 
observed in Table 1 is different for individual enzymes because the cleavage rates are slower for 
certain enzymes, with α-Dmannosidase exhibiting the highest rate and β-D-N-acetyl 
glucosaminidase and α-L-fucosidase exhibiting lower rates. In the case of L-fucosidase, the 
substrate with the benzyloxy spacer resulted in inefficient cleavage as the active site of the enzyme 
has a tyrosine that stacks up against the phenyl ring, thereby inhibiting the rate of cleavage. 
However, when glucose is attached directly to L-fucose as shown in entry 6, Table 3-1, the rate is 
faster. 
One concern related to the practicality of this assay when we transition to human clinical 
samples is the presence of interferences such as other saccharides such as galactose, lactose, etc. 
Additionally, glucose and/or enzymes that could degrade natural substrates to produce glucose 
may be present in the sample. To avoid false positives or negatives, we decided to measure the 
presence of glucose in the sample before and after addition of the substrate. The difference between 
the two readings is expected to indicate the presence of the associated enzyme. As a first step, we 
purchased artificial urine (Innovating Science Artificial Urine FSE was purchased from Fisher 
Scientific, Pittsburgh, PA) and spiked it with different carbohydrates such as D-galactose, D-
mannose, and lactose. As seen in Figure 8, entries I (D-galactose), II (D-mannose), and III 
(lactose), ΔI is negligible, indicating that these sugars do not react with glucose oxidase or the 
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mediator in the coated screen printed electrodes. Next, we spiked one of the enzymes, β-
glucuronidase without its substrate (entry IV). ΔI for this sample was also negligible, indicating 
that β-glucuronidase does not interact with anything in the sample to produce glucose. When we 
added the substrate to the sample containing β- glucuronidase, (entry V) we observed glucose 
released, indicating that the enzyme present in the sample reacts with the substrate to release 
glucose. We also added 1 mM glucose to the samples containing D-galactose, D-mannose, and 
lactose, respectively (entries VI, VII, and VIII), and we observed that glucose oxidase and mediator 
in the screen printed electrodes reacts only with glucose. The results indicate the following: (1) 
Glucose oxidase in the test strips reacts only with glucose and not with closely related sugars such 
as D-galactose, etc. (2) The glycosidase reacts specifically with its substrate. (3) The difference in 
current before and after addition of the substrate indicates the presence/absence of the glycosidase. 
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Figure 3-8 Different compounds were spiked in Innovating Science Artificial Urine FSE 
(Fischer Scientific, Pittsburgh, PA) as indicated in the entries and glucose was measured after 1 
h.  (I) 1 mM D-galactose, (II) 1 mM D-mannose, (III) 1 mM lactose, (IV) 15000 U mL−1 β-
glucuronidase, (V) 1 mM compound D was incubated with β-glucuronidase 15000 U mL−1 at 37 
°C for 1 h. (VI) 1 mMD-galactose plus 1 mM D-glucose, (VII) D-mannose plus 1 mM D-glucose, 
(VIII) lactose plus 1 mM D-glucose. The current was measured in amperes after 100 s using an 
amperometric i−t curve at a working potential of 0.00 V. The y axis, ΔI, represents the difference 
in current before and after addition of the reagent. All experiments were performed in triplicate 
independently on different days. 
Since our long-term goal is to detect glycosidases in environmental or clinical samples, we 
tested the limit and time course of detection for one of the glycosidases. The limit of detection 
using a higher substrate concentration was determined to be 0.01 U/mL in 1 h (Figure 3-9).  
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Figure 3-9 Limit of detection studies. Compound A was incubated with different 
concentrations of α-mannosidase at 37 °C for 1 h. Inset: Expanded region from 0.0 to 1.0 U/mL. 
The current was measured in amperes after 100 s using an amperometric i−t curve at a working 
potential of 0.00 V. The y axis, ΔI, represents the difference in current between the negative control 
(no enzyme) and the sample. The x-axis represents different concentrations. All experiments were 
performed in triplicate independently on different days. 
Next, we performed time course studies. We found that 0.1 units of mannosidase can be 
detected using this assay in 15 min (Figure 3-10). This is a distinct advantage of this biochemical 
assay since most end-users suggest a test-to-result time of less than 20 min. For example, recent 
publications that focused on the needs of end users that use point of care diagnostics for sexually 
transmitted diseases clearly stated that they would like a test-to result time of less than 20 min as 
there is a social stigma attached to these diseases100,101. We anticipate better performance of this 
biochemical assay as improved substrates that result in faster rates are developed. 
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Figure 3-10 Time course studies. Compound A was incubated with α-mannosidase at 37 
°C. The current was measured at 5 min, 10 min, and 15 min, respectively. The current was 
measured in amperes after 100 s using an amperometric i−t curve at a working potential of 0.00 
V. The y axis, ΔI, represents the difference in current between the negative control (no enzyme) 
and the sample. All experiments were performed in triplicate independently on different days. 
3.4 Conclusions 
In summary, we have developed a panel of glycoconjugates bearing a glucose derivative. 
Glucose is released when the respective enzymes are introduced, which is measured 
amperometrically using a standard three electrode electrochemical cell. This assay can be 
integrated in existing glucose meters as a method to detect these glycosidases. We note that a 
limitation of the present study is that artificial urine samples were used. Human urine samples 
from patients are expected to be more complex as they may contain interferences that may interact 
with either the substrate or the enzymes. Further optimization in substrate design and assay 
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conditions that emphasize enzyme−substrate interactions over other interactions will be required 
when we transition this work from the laboratory to the clinic; however, as a first step, this assay 
shows promise in glycosidase detection using ubiquitous glucose meters. Since glycosidase release 
in body fluids can be indicative of the presence of a pathogen and or a disorder, this assay could 
potentially be used to monitor human diseases in a point of care setting. Furthermore, multiple 
glycosidases or other enzymes can be detected rapidly using multiple substrates; this information 
could assist physicians in identifying the causative agent(s) causing the illness. This part of work 
was published in analytical chemistry (Anal. Chem. 2016, 88, 4248-4253). 
3.5 Experiment section 
3.5.1 Electrochemical System  
The initial proof of principle studies were performed using printed disposable system 
(Figure 3.11), which contains a working electrode, a reference electrode and a counter electrode. 
The electrode was coated with coating solution achieved by mixing 1ml of solution A (2 mM Bi 
(NO3)3·5H2O and 3 mM SeO2 in 1:20 diluted nitric acid) and 2 ml of solution B (2 mM K3Fe(CN)6, 
2 mM FeCl3, 0.1 M KCl and 10 mM HCl) followed by cyclic voltammetry scanning from +0.60 
V to -0.20 V at 20 mVs-1 for 30 cycles. After the coating, the electrode was activated by cycling 
from 0.35 V to -0.05 V at 50 mVs-1 for 30 times in solution C (0.1 M KCl and 10 mM HCl). 5.0 
mg of Glucose oxidase (GOD) was dissolved in 1 mL of 0.5% chitosan solution (prepared in 2% 
acetic acid) and the resulting GOD (10 µL) solution was dropped on the surface of the electrode 
to form a GOD layer. The GOD layer was air dried to form a firm coated layer on the working 
electrode.  
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Figure 3-11 The printed disposable electrode used in the assay. 
3.5.2 Detection of Glycosidases 
 All enzymes were incubated with their respective substrates (100 µL, 2 mM in DI water) 
at 37 °C for 1 h. A volume of 20 µL of the solution was used to detect the current using the printed 
electrode system. For α-mannosidase, a solution of the enzyme (100 µL, 10 U mL−1 in 0.05 M 
citrate buffer, pH 4.5) was added to a solution of A. For β-galactosidase, a solution of the enzyme 
(100 μL, 100 U mL−1 in PBS buffer, pH 7.4) was added to a solution of C. For β-glucuronidase, a 
solution of the enzyme (100 μL, 15000 UmL−1 in phosphate buffer, pH 6.8) was added to a solution 
of D. For β-N-acetylglucosaminidase, a solution of the enzyme (100 μL, 10 U mL−1 in 0.05 M 
citrate buffer, pH 5.0) was added to a solution of F. For α-L-Fucosidase, a solution of the enzyme 
(100 μL, 10 U mL−1 in 0.05 M citrate buffer, pH 5.5) was added to a solution of G or H. 
3.5.3 Limit of Detection Studies 
A solution of α-mannosidase (50 μL, 20−0.02 U mL−1 in 0.05 M citrate buffer, pH 4.5) 
was added to a solution of A (50 μL, 4 mM in DI water). The mixture was incubated at 37 °C for 
1 h. A volume of 20 μL of the mixture was used to detect the current using the printed electrode 
system. 
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3.5.4 Time Course Studies  
A solution of α-mannosidase (250 μL, 20 U mL−1, 1 U mL−1, or 0.2 U mL−1 in 0.05 M 
citrate buffer, pH 4.5) was added to a solution of A (250 μL, 2 mM in DI water). The mixture was 
incubated at 37 °C. In total, 20 μL of the solution was taken to detect the current using the printed 
electrode system at 5, 10, and 15 min, respectively. 
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4 CHAPTER 4. TOWARD THE DEVELOPMENT OF THE NEXT GENERATION OF 
A RAPID DIAGNOSTIC TEST: SYNTHESIS OF 
GLYCOPHOSPHATIDYLINOSITOL (GPI) ANALOGUES OF PLASMODIUM 
FALCIPARUM AND IMMUNOLOGICAL CHARACTERIZATION 
4.1 Introduction 
Malaria parasites, particularly Plasmodium falciparum, contribute to over 200 million 
clinical infections and about 500000 deaths per annum (Figure 4-1)102,103. According to World 
Health Organization, in 2016 an estimated 216 million cases of malaria occurred worldwide and 
445,000 people died104. The majority of these infections occurred in Africa and most of them were 
children under 5 years old. Malaria is transmitted by the bites of infected female Anopheles 
mosquitoes, also called "malaria vectors." There are 5 parasite species that cause malaria in 
humans, named P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Among them, P. 
falciparum and P. vivax pose the greatest threat. 
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Figure 4-1 The distribution of malaria.. The endemic areas are Africa, south-east Asia 
and Latin America. The picture was adopted online from CDC105. 
In the early stage of the malaria infections, typically 10~15 days, only the mild symptoms 
such as headache, chills and flu-like symptoms shows up. However, if left untreated within 24 
hours, P. falciparum can lead to severe sick, often cause death.  
The lack of effective vaccines and emergence of drug and insecticide resistance pose major 
challenges for malaria control. Rapid and accurate diagnosis of malaria is critical for the success 
of any malaria control program. Indeed, the WHO recommends that malaria treatment should be 
based on diagnostic confirmation of infection106. Although microscopic diagnosis of malaria has 
been a standard practice for a long time, rapid diagnostic tests (RDTs) have more recently become 
very useful tools for malaria diagnosis, especially in Africa, where most malaria cases occur. 
Commercial RDTs detect three different antigens, namely histidine rich protein II (HRP2), lactose 
dehydrogenase (LDH), and aldolase107. LDH and aldolase tests perform poorly at low antigen 
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concentrations (<1000 parasites/µL), and, therefore, the HRP2 test, which is specific to P. 
falciparum and more sensitive (∼200 parasites/µL), is preferred. Unfortunately, significant 
parasite populations with HRP2 deletions have emerged in several endemic regions, e.g., Amazon 
basin of South America, leading to high false negatives and undesirable clinical outcomes. 
Furthermore, residual HRP2 levels persisting after the parasite has been eliminated from the 
bloodstream as determined by other methods leads to false positives, which makes it difficult to 
determine if patients have completely cleared parasites after treatment in resource-poor 
settings108,109. To overcome limitations related to current RDTs, we have attempted to identify new 
targets, and in this report, we focus on a unique target, which is malaria GPI 
(glycophosphatidylinositol) anchors.  
GPI anchors are ubiquitous in eukaryotic cells and are particularly abundant in parasites in 
the form of free lipids or attached to proteins. It is well-known that GPIs are one of the parasite 
products involved in modulating the host immune system to produce inflammatory mediators. 
Development of natural antibodies to GPI is associated with clinical immunity to malaria110. We 
reasoned that GPIs could be targets for RDTs for the following reasons. (1) Compared to the 
functionally unknown HRP2, GPIs are unlikely to be absent throughout the parasite life cycle due 
to their functional importance. Specifically, GPIs function as anchors for a variety of important 
surface proteins such as MSP-1, MSP-2, and MSP-4. GPI anchors account for over 95% of post-
translational carbohydrate modifications in malaria parasite. (2) GPIs are abundant and present on 
the surface of infected red blood cells (RBCs) or the parasite, which makes it easy for the antibody 
to capture the parasite. (3) GPIs from P. falciparum are structurally distinct from human GPIs. 
Figure 4.2 shows the difference between P. falciparum and mammalian GPIs. Therefore, 
antibodies raised against malaria are not expected to recognize human or other parasite GPIs. 
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Figure 4-2 The structure of P. falciparum and human GPI. 
Glycosylphosphatidylinositol (GPI) is a large family of glycolipids that can be attached to 
the C-terminus of a protein during posttranslational modification. GPI anchors isolated from 
different species share a unique core structure; a phosphatidylinositol (PI) moiety attached to the 
reducing terminal of a glucosamine residue through an α1−6 glycoside linkage, and a distal 
nonreducing mannose residue linked to an ethanolamine phosphate bridge at the C-6 hydroxyl 
group of mannose, through which proteins are attached (Figure 4-2). Several groups have analyzed 
the structure of P. falciparum GPIs. Gerold et al. first identified the glycan moiety structure of two 
mature GPIs: ethanolamine−phophate−6(Man1−2)Manα1−2Manα1−6Man1−4GlcN−PI and 
ethanolamine−phophate−6Manα1−2Manα1−6Man1−4GlcN−PI, which were confirmed later by a 
mass spectrometric analysis111,112. The latter study also revealed heterogeneity in fatty acyl 
substituents on the inositol ring, with palmitic (major) and myristic (minor) acids at the C-2 
position of myo-inositol. A synthetic GPI 
NH2−CH2−CH2−OPO3−(Manα1−2)6Manα1−2Manα1−6Manα1−4GlcNH2α1−6myo-inositol-
(1,2-cyclic phosphate) was evaluated as candidate antitoxic vaccine, and the anti-GPI antibodies 
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generated were found to effectively neutralize pro-inflammatory activity in a rodent malarial 
model. 
Encouraged by these studies, we envisioned the development of antibodies to P. falciparum 
GPIs for integration in RDTs to accurately detect the parasite in blood samples. Unfortunately, 
isolating GPIs from the parasite in sufficient amounts with consistency and high purity is not a 
trivial endeavor. Fortunately, advances in glycan synthesis can generate extremely pure chemically 
defined complex glycoconjugates (human and parasite GPI anchors) in appreciable 
quantities113,114,115,116,117,118,119,120,121,122,123,124,125. Here, we present the design, synthesis of natural 
and pseudo-P. falciparum GPI analogues, generation of antibodies using GPI−protein conjugates, 
and initial immunological characterization (Figure 4-3, Figure 4-4). 
 
Figure 4-3 Our strategy of detection of P. falciparum. 
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Figure 4-4 The structure of Pseudo-GPI anchors. 
4.2 Results and Discussions 
4.2.1 Chemical synthesis  
The structures of the target compounds are depicted in Figure 4-4. We focused our studies 
on the synthesis of the naturally occurring P. falciparum GPI hexasaccharide 1 and two unnatural 
analogs, the hexasaccharide, 2 and the pentasaccharide 3. The latter were synthesized because the 
diols leading to the inositol analogs were relatively easy to synthesize in large amounts. Studies 
using these analogs are important in understanding the role of inositol in antibody recognition. We 
used a short alkyl chain instead of longer lipids present in naturally occurring GPI anchors 
primarily because the lipids are embedded in the lipid membrane, leaving the glycan region 
exposed. Antibodies raised against these compounds are expected to recognize the exposed glycan 
portion of the GPI anchor. If our working hypothesis that longer lipid chains are not significant for    
antibody recognition is proven to be incorrect, we can readily produce GPIs with longer lipids 
because the modular nature of our synthetic strategy allowed us to incorporate lipids at a later stage 
in the synthesis. The primary amine of the phosphoethanolamine in all three compounds was 
conjugated with a carrier protein to generate antibodies. We synthesized GPI anchor analogs 1, 2, 
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and 3 and their corresponding keyhole limpet hemocyanin (KLH) protein conjugates GPI1, GPI2, 
and GPI3. 
From the retrosynthetic analysis of GPI3 in Figure 4-5, we noticed that we need to 
synthesize a tetra-mannoside and a pseudo-disaccharide. Tetra-mannoside can be further divided 
into three mannose donor or acceptor. The pseudo disaccharide can be synthesized by the 
glycosylation of glucoseamine donor and suitable protected inositol acceptor. The phosphate lipids 
and phosphate ethanolamine can be synthesized readily. 
 
Figure 4-5 Retrosynthetic analysis of GPI3 
To generate tetrasaccharide 4-21, we synthesized suitably protected D-mannose 
monosaccharide derivatives 4-8, 4-12, 4-14. (Scheme 4-1 & 4-2)126,127. Briefly, the D-mannose 
was converted into acetyl protected orthoester 4-4 using a three-step procedure with an overall 
yield of 65%. After acetate deprotection using K2CO3 in MeOH and benylation under NaH and 
BnBr, per-benzyl protected orthoester 4-6 was achieved. Open the orthoester ring using TsOH in 
DME-H2O to furnish the hemiacetal 4-7, which can be readily to convert to imidate 4-8. 
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Scheme 4-1. The synthesis of mannose fragment 4-8.  
 
Scheme 4-2. The synthesis of mannose fragment 4-12 and 4-14. 
The synthesis of fragment 4-12 and 4-14 started from the same mannose derivative 4-5. 
Selectively protect the primary alcohol with TIPS and benzylation at 3 and 4 positions to provide 
compound 4-10. The orthoester ring was open by allyl alcohol and BF3·OEt2 to achieve compound 
4-11, which can be deacetylation to give fragment 4-12.  After putting a benzoyl group at 2 position 
and deprotecting silyl group under AcCl in MeOH, the last mannose fragment 4-14 was achieved. 
We choose the allyl group as a protecting group in several of the fragments because it can 
be readily removed to provide the hemiacetal, which can be further elaborated or hydrogenated to 
provide a three-carbon spacer present in the final compounds. Additionally, the allyl group is 
compatible with several of the protection and deprotection strategies employed in our syntheses. 
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Coupling of 4-8 with 4-14 resulted in the desired exclusive α product in high yield (Scheme 4-3). 
Selective removal of the acetate group using AcCl in MeOH to provided acceptor 4-16. 
 
Scheme 4-3. The synthesis of disaccharide 4-16. 
To synthesize the disaccharide 4-19, glycosylation of 4-8 and 4-12 using TMSOTf as 
promoter to yield disaccharide 4-17. Next, the allyl group was deprotected by using PdCl2−AcOH, 
and the resulting alcohol was converted to the corresponding imidate 4-19 in 60% yield over two 
steps (Scheme 4).  
 
Scheme 4-4. The synthesis of mannose fragment 4-19. 
Next, a [2 + 2] approach was used to synthesize tetrasaccharide 4-2 (Scheme 4-5). 
Glycosylation (2 + 2) of the D-mannose disaccharide acceptor 4-16 and donor 4-19 in the presence 
of catalytic amount of TMSOTf in dichloromethane at −40 °C produced the tetrasaccharide 4-20 
in 80% yield. The allyl group in tetrasaccharide 4-20 was selectively deprotected by PdCl2-HOAc, 
and the alcohol was converted to the corresponding imidate donor 4-21, which were ready for 
further elaboration to the target compounds GPI3. 
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Scheme 4-5. The synthesis of tetrasaccharide donor 4-21. 
Next, we synthesized suitably protected glucosamine donor 4-26 and inositol acceptor 4-
36. For the synthesis of compound 4-26, starting from glucoseamine hydrochloride shown in 
Scheme 4-6. First, the amine group was converted into azide under triflic azide in MeOH-H2O and 
catalytic amount of CuSO4. After peractylation and selective deprotection of anomeric acetyl 
group using hydrazine acetate in DMF, the hemiacetal was provided, which can be further 
converted into the imidate 4-26 with 75% yield. 
 
Scheme 4-6. The synthesis of glucoseamine donor 4-26. 
The synthesis of inositol acceptor is shown in Scheme 4-7. Inositol itself has nine possible 
stereoisomers, which makes it difficult to achieve the suitable protected inositol donor from naked 
inositol. Since inositol has the same chiral center as glucose, we decided to use methyl glucoside 
4-27 as starting material, through Ferrier rearrangement to achieve the inositol ring. Selective 
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protection of primary alcohol was furnished by TIPSCl and imidazole in DMF. Without any 
purification, it is further used to do perbenzylation and TIPS deprotection using AcCl in MeOH-
DCM to provide compound 4-30. Then primary hydroxyl group was oxidized to aldehyde using 
DMSO and SO3Py, followed by converting it to the corresponding enol form under treatment of 
K2CO3 and Ac2O in CH3CN. The oxidization reaction has to been complete in 100%. Otherwise, 
the rearrangement reaction is a problem, because the side product has a similar rf value with4-32. 
The next reaction is the most important reaction in the scheme, converting the glucose ring to 
inositol ring by Ferrier rearrangement. The mechanism of this rearrangement is shown below 
(Scheme 4-8). Briefly, Hg2+ is electrophilic addition with double bond, followed by the attack of 
water molecule. After glucose ring open and re-close, the inositol ring is formed. This 
rearrangement was achieved by firstly utilizing Hg(OCF3CO)2 in Acetone and water, then treating 
with NaOAc and NaCl with 56% yield. Ketone was reduced to alcohol under NaBH(OAc)3 in 
HOAc and CH3CN with 82% yield. A two steps protection and deprotection protocol – firstly 
protecting 1,3-diol with vinyl ethyl ether and deprotecting acetyl group using NaOMe, followed 
by allyl protection by AllBr and NaH in DMF, last deprotecting vinyl ethyl ether by 2N HCl, was 
used to convert acetyl group to allyl group. After selectively install Bn or PMB group on axial 
hydroxyl group, the inositol acceptors 4-36 a and 4-36 b were achieved. The PMB derivative was 
used to install fatty acid later on. 
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Scheme 4-7. The synthesis of inositol acceptor 4-36. 
 
Scheme 4-8. The mechanism of Ferrier rearrangement. 
With the glucosamine donor and inositol acceptor in hand, glycosylation was performed at 
-30 oC, TMSOTf as promoter in DCM (α/β=3:1, Scheme 4-9). Deprotection of the acetate groups 
using Zemplén conditions, followed by protection of the 4,6-hydroxyl and 3-hydroxyl group by 
benzylidene acetal and benzyl ether, respectively, yielded the completely protected pseudo-
disaccharides. The α, β isomers were purified by column chromatography at this stage and 
characterized by 1D and 2D NMR spectroscopy. The anomeric proton in the α isomer resonates at 
δ 5.04 ppm and resonates at δ 4.84 ppm in the β-anomer. Next, the benzylidene acetal was 
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selectively opened by sodium cyanoborohydride to yield the desired disaccharide acceptor 4-41 in 
74% yield. 
 
Scheme 4-9. The synthesis of pseudo-disaccharide 4-41. 
With the two fragments in hand, we reacted the tetrasaccharide donor 4-21 and pseudo 
disaccharide acceptor 4-41 at −10 °C by using TMSOTf (0.1 equiv) as promoter to afford the 
desired hexasaccharide 4-42, as shown in Scheme 4-10. The α isomer was the only isomer isolated; 
however, the yields were low and variable. Careful examination of the byproducts indicated that 
the TIPS group in the donor was being deprotected under the reaction conditions, presumably by 
the acidic promoter. To avoid this side reaction, we lowered the concentration of TMSOTf and 
decreased the reaction temperature to −40 °C to obtain a higher yield of 70%. Next, the acetate 
and benzoate esters in 4-42 were hydrolyzed using Zemplén conditions, and the hydroxyl groups 
in 4-43 were protected as the benzyl ether to provide 4-44. The silyl group in 4-44 was deprotected 
using AcCl in MeOH to yield the free hydroxyl 4-45 in quantitative yield. 
The next step, which was the introduction of the phosphoethanolamine was problematic. 
We followed literature procedures, which suggested mixing the two fragments in a suitable 
solvent, followed by the addition of pivaloyl chloride to introduce the phosphoethanolamine unit 
to 4-45 via the free hydroxyl group. Unfortunately, the only product isolated was the pivaloate 
ester of the alcohol 4-45. Fortunately, we found a solution to this problem by modifying the 
addition sequence. We premixed the H-phosphonate ester with pivaloyl chloride in anhydrous 
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pyridine, followed by addition of 4-45 to yield the desired product 4-46 in quantitative yield. 
Global deprotection of all the benzyl ethers and azide reduction in 4-46 using Pd(OH)2−H2 under 
atmospheric conditions, followed by purification using a Biogel P-2 column, yielded the fully 
deprotected GPI analog 3 in quantitative yield. All intermediates and final products were 
characterized by 1HNMR, C13NMR, HSQC NMR, and HRMS spectroscopy.  
 
Scheme 4-10. The synthesis of GPI analogue 3.  
The synthesis of GPI analogue 1 and 2 were achieved by our former postdoc, Dr. Bharat 
Gurale. 
With the three GPI analogues in hand, next the three synthesized GPI moieties were 
coupled to keyhole limpet hemocyanin (KLH), a commonly utilized protein molecule as a carrier 
protein. The use of a larger carrier protein is necessary in immunization protocols because a small 
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molecule such as a short peptide or, in our case, GPI moiety may not be immunogenic enough to 
elicit a strong immune response. Coupling glycans to a larger carrier molecule such as the keyhole 
limpet hemocyanin (KLH) has been shown to lead to successful immunization. KLH is the most 
commonly used carrier protein because it has a significantly higher immunogenicity as compared 
to that of other proteins. To this end, compounds 1, 2, and 3 were conjugated with preactivated 
Imm-Link KLH (Novobios) to provide GPI1, GPI2, and GPI3, respectively, according to 
manufacturer’s protocol (Scheme 11). Briefly, the preactivated KLH was treated with the large 
excess of glycan (KLH/glycan; 1:∼200 ratio). After conjugation, unreacted glycans were removed 
by dialysis against distilled water. KLH is an approximately 400 kDa multidomain protein 
complex128, and characterization of conjugates was not practical by mass spectroscopy. However, 
the synthesized conjugates were analyzed using colorimetric methods; the glycan loading was 
determined to range between 15 and 17% using the procedures reported by Zou et al129,130. 
 
Scheme 4-11. The synthesis of GPI-KLH conjugates. 
4.2.2 Biological Assays (Done by Dr. Yun He) 
Polyclonal antibodies using rabbits were raised against each of GPI−KLH conjugate with 
two rabbits per conjugate. (Figure 4-6) All rabbits immunized with GPI1, GPI2, or GPI3 had 
positive antibody responses, with IgG titer steadily increasing over the 70 day course. Antisera 
from rabbits 1−4, immunized with GPI1 or GPI2, exhibited reactivity against GPI1 and GP2 but 
did not exhibit any cross-reactivity with GP13. Similarly, anti-GPI3 sera from rabbits 5 and 6 
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exhibited reactivity with GPI3 but minimal (rabbit 5) or no (rabbit 6) cross-reactivity with GPI1 
or GPI2. This pattern of reactivity indicates that the antibodies in these sera may be directed to 
inositol residue as the primary difference between GPI1 or GPI2 and GPI3 is in this residue. 
Interestingly, immune sera raised against GPI1 showed a higher level of reactivity against GPI2 
than GPI1. Structurally, GPI1 and GPI2 share an identical pseudo-inositol residue except for the 
presence of additional distal mannose in GPI1. This cross-reactivity between GP1 and GP2 
indicates the epitope recognized by the elicited IgG does not lie on the non-reducing mannose end. 
 
Figure 4-6 Anti-GPI antibody titers in six immunized rabbits measured by Luminex assay. 
Luminex assay using three synthetic GPI analogues against rabbit antisera harvested at different 
days. A total of six rabbits were immunized with the three generated synthetic GPIs: 1, 2, and 3. 
Rabbits 1 and 2 were immunized with GPI1; rabbits 3 and 4 with GPI2; and rabbits 5 and 6 with 
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GPI3. The rabbits were bled before the immunization procedure (day 0 sample) and subsequently 
on days 7, 21, 35, and 56 post-immunization. The Luminex assay was used to measure the anti-
GPI antibodies titers elicited by the rabbits. All rabbits immunized with GPI1, GPI2, or GPI3 had 
positive antibody responses, with IgG titer steadily increasing over the 70 day course. Antisera 
from rabbits 1−4, immunized with GPI1 or GPI2, exhibited reactivity against GPI1 and GPI2 but 
did not exhibit any cross-reactivity with GPI3. Similarly, anti-GPI3 sera from rabbits 5 and 6 
exhibited reactivity with GPI3 but minimal (rabbit 5) or no (rabbit 6) cross-reactivity with GPI1 
or GPI2. 
We tested the reactivity pattern of the rabbit antisera, both preimmunization (preimmune 
sera) and postimmunization (immune sera), against native GPI isolated from P. falciparum (Figure 
4-7). The immune sera from rabbits 1, 3, and 5 and the hyperimmune sera used showed statistically 
significant increase in reactivity compared to that of preimmune sera (P < 0.05), suggesting that 
these rabbits responded strongly to the synthetic GPI immunogen. Immune sera from rabbit 
number 2 (P = 0.527), rabbit 4 (P = 0.125), and rabbit 6 (P = 0.104) were not statistically 
significant. This binding affinity was comparable to reactivity obtained with natural human hyper 
immune sera used as positive control (Figure 3). Overall, this data suggests that antibodies 
generated against the synthetic analogues of GPI can recognize native parasite GPI antigens and, 
therefore, this antigen−antibody system based on synthetic GPIs that can be exploited to develop 
RDTs. Studies to demonstrate these anti-GPI antibodies do not cross-react with GPI moieties from 
other infectious diseases are ongoing. 
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Figure 4-7 Binding affinity of P. falciparum native GPI to rabbit anti-GPI antibodies. 
ELISA assays were performed to determine if the anti-GPI antibodies generated in the immunized 
rabbits were capable of detecting GPIs from P. falciparum parasites. Native P. falciparum GPIs 
were dissolved in methanol and coated to ELISA plates at a concentration of 40 ng/mL. Both 
preimmune and immune (56 days post-immunization) sera from the six rabbits were tested in 
triplicate. As a control, human hyperimmune serum (HUMAN) was also tested. The mean 405 nm 
absorbance was recorded for each sample. Immune sera from rabbits 1, 3, and 5 and the 
hyperimmune human sera showed significant affinity for the native P. falciparum GPI. 
4.3 Conclusion 
We successfully synthesized three synthetic GPI analogues and developed antibodies 
against these analogues. Antibodies raised against these synthetic GPI−protein conjugates 
exhibited binding to the synthetic GPIs. The results also indicated that the antibodies rasied against 
the pseudoinositol synthetic GPI are specific to the GPIs containing this pseudoinositol moiety. 
88 
Antisera raised against synthetic GPI can capture native GPI, indicating the potential use of these 
structures as targets for diagnostic assays. 
4.4 Experimental Section 
4.4.1 Chemical synthesis and characterization 
Glycosylation reactions were performed under argon with solvents dried using a solvent 
purification system (Innovative Technology). All chemical reagents were of analytical grade and 
used as supplied without further purification unless indicated. The acidic ion-exchange resin used 
was Amberlite IR 120 (H+) resin. Analytical thin layer chromatography (TLC) was performed on 
silica gel 230−400 mesh (Sicicycle). Plates were visualized under UV light, by staining with acidic 
CeH8Mo3N2O12 followed by heating, or both. Column chromatography was performed on silica 
gel (230−400 mesh). 1H and 13C NMR spectra were recorded on Bruker 400 MHz spectrometer. 
Chemical shifts are reported in δ (ppm) units using 13C and residual 1H signals from deuterated 
solvents as references. Spectra were analyzed with MestreNova (Mestrelab Research). 
Electrospray ionization mass spectra were recorded on a Micromass Q\T 2 (Waters), and data were 
analyzed with MassLynx 4.0 (Waters) software. Reported yields refer to spectroscopically and 
chromatographically pure compounds that were dried under high vacuum (10−2 mbar) before 
analytical characterization unless otherwise specified. An Imm-Link KLH (Amine) Immunogen 
Conjugation Kit was purchased and used according to instructions given by Novus. 
Penta-O-acetyl-α/β-D-mannopyranose (4-2) 
 
To a stirring solution of iodine (1.12 g, 4.25 mmol) in Ac2O (100 mL) at 0 °C, D-mannose 
(20.0 g, 111.2 mmol) was added in a small portion. The reaction mixture was stirred at 0 °C for 30 
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min and then allowed to warm to rt. After 30 min the reaction mixture was diluted with DCM and 
then washed with cold Na2S2O3 solution (2 × 125 mL). The organic phase was washed with 
NaHCO3 solution (4 × 125 mL), dried over Na2SO4, and concentrated under reduced pressure to 
afford the pentaacetates 4-2 as a yellow syrup, which was used for the next step without further 
purification. 
Tetra-O-acetyl-α-D-mannopyranosyl bromide (4-3) 
 
To a stirring solution of compound 4-2 in DCM at 0 oC, HBr in acetic acid (30%, 90 mL) 
was added. The reaction mixture was stirred overnight at rt and then poured into ice-water. The 
layers were separated and the organic phase was washed with saturated NaHCO3 solution until no 
bubbles, dried over Na2SO4, and concentrated under reduced pressure to afford compound 4-3 as 
a yellow syrup, which was used for the next reaction without any purification. 
3,4,6-Tri-O-acetyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (4-4) 
 
To a stirring solution of bromide in MeOH (150 mL), 2,6-lutidine (25 mL) in CHCl3 
(150 mL) was added. The reaction mixture was stirred for 24h at rt. Then DCM was added 
to dilute it. The resulting mixture was washed with water, brine and dried with Na2SO4. 
Concentration under reduced pressure and subjection to flash column to yield compound 4-4 as a 
yellow syrup (26.2 g, 65% from mannose). 
1,2-O-(1-Methoxyethylidene)-β-D-mannopyranose (4-5) 
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To a stirring solution of orthoester 4-4 (26 g, 71.8 mmol) in MeOH, anhydrous K2CO3 (0.8 
g, 5.8 mmol) was added. The reaction mixture was stirred at rt for 2 h and monitored by TLC. 
After reaction was completed, MeOH was removed under reduced pressure to afford triol 4-5, 
which was used for the next step without any purification. 
3,4,6-Tri-O-benzyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (4-6) 
 
To a stirring solution of triol 4-5 (36 mmol, assuming 100% yield) in DMF at 0 oC, NaH 
(7.2 g, 180 mmol) was added in a small portion. The reaction mixture was stirred at 0 oC for 30 
min. BnBr (17.0 mL, 144 mmol) was added dropwise. The reaction was stirred at rt for 24 h. Upon 
completion of the reaction as monitored by TLC, water and EtOAc were added. The layer was 
separated and the aqueous layer was extracted with EtOAc. The combined organic layer was 
washed with brine, dried over Na2SO4, and concentrated to dry. The residue was subjected to flash 
column eluting with Hexane:EtOAc (10:1) to furnish compound 4-6 as a yellow syrup (15.5 g, 
85%). 
2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl trichloroacetimidate (4-8) 
 
To a stirring solution of compound 4-6 (15.5 g, 30.6 mmol) in DME and water, TsOH (517 
mg, 3.0 mmol) was added. The reaction mixture was stirred at rt until the starting material was 
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consumed as monitored by TLC. The reaction was diluted with EtOAc and separated. The aqueous 
layer was extracted with EtOAc. The combined organic layer was dried with Na2SO4, and 
concentrated to dryness. The residue was dissolved in anhydrous DCM. The reaction mixture was 
cooled to 0 oC, followed by the addition of DBU (448 µL, 3.0 mmol) and CCl3CN (15.34 mL, 153 
mmol).  The reaction was allowed to warm to rt and stirred for another 2h. 
Upon the reaction was completed, the solvent was removed under reduce pressure. The 
residue was subjected to flash column and elute with Hexane/EtOAc (8:1) to get the imidate as a 
white solid (15.5 g, 24.5 mmol). 
3,4-Di-O-benzyl-6-O-triisopropylsilyl-1,2-O-(1-methoxyethylidene)-β-D-
mannopyranose (4-10) 
 
To a stirring solution of triol (36 mmol, assuming 100% yield) in DMF at 0 oC, imidazole 
(3.68 g, 54 mmol) was added, followed by the addition of TIPSCl (8.33 g, 43.2 mmol). The 
reaction mixture was stirred at rt for 6 h. EtOAc and water were added, and the aqueous layer was 
extracted with EtOAc. The combined organic layer was washed with brine, dried over Na2SO4, 
and concentrated to dry. The residue was dissolved in DMF and cooled to 0 oC, NaH (4.32 g, 108 
mmol) was added. The reaction mixture was stirred at 0 oC for 30 min. Then BnBr (10.7 mL, 90 
mmol) was added dropwise. The resulting mixture was stirred at rt overnight. EtOAc and water 
were added, and the aqueous layer was extracted with EtOAc. The combined organic layer was 
washed with brine, dried over Na2SO4, and concentrated to dry. The residue was subjected to flash 
column and eluted with hexane/EtOAc (10:1) to achieve compound 4-10 as a white syrup (15.5g, 
27 mmol). 
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Allyl 2-O-acetyl-3,4-di-O-benzyl-6-O-triisopropylsilyl-α-D-mannopyranoside (4-11)      
 
To a stirring solution of orthoester 4-10 (15.5 g, 27 mmol) in dry DCM, allylic alcohol 
(17.02 mL, 250.3 mmol) and activated molecular sieves (4Å) were added. The reaction mixture 
was stirred for 10 min at rt. Then BF3·Et2O (1.7 mL, 13.5 mmol) was added. The reaction mixture 
was further stirred for 2 h then a saturated NaHCO3 solution was added. The mixture was extracted 
with DCM and the combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated to dryness. The crude product was purified by flash chromatography eluting with 
hexane/EtOAc (9:1) as a white syrup (14.6 g, 24.3 mmol). 
Allyl 2-O-benzoyl-3,4-di-O-benzyl-6-O-triisopropylsilyl-α-D-mannopyranoside (4-13) 
 
To a stirring solution of compound 4-11 (14.6 g, 24.3 mmol) in MeOH, 30% NaOMe 
solution in MeOH was added. The reaction mixture was stirred at rt for 1h. The solution was 
neutralized with Amberlite® IR 120 (H+) resin, filtered and concentrated to dry. The residue was 
dissolved in dry DCM at 0 oC, NEt3 (5.1 mL, 36.5mmol) was added, followed by the addition of 
BzCl (3.4 mL, 29.2 mmol). The reaction mixture was stirred at rt for 4h. The solvent was removed 
under reduce pressure and the residue was subjected to flash column eluting with hexane/EtOAc 
(10:1) to yield compound 4-13 as a white syrup (14.5 g, 21.9 mmol). 
Allyl 2-O-benzoyl-3,4-di-O-benzyl-α-D-mannopyranoside (4-14) 
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To a stirring solution of compound 4-13 (14.5 g, 21.9 mmol) in DCM-MeOH at rt, AcCl 
(7.7 mL, 110 mmol) was added. The reaction mixture was stirred at rt until the starting material 
was consumed checking by TLC. The solvent was removed under reduce pressure and the residue 
was subjected to flash column eluted with hexane/EtOAc (5:1) to yield acceptor 4-14 as a white 
syrup (10.5 g, 20.8 mmol). 
Allyl (2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-(1→6)-2-O-benzoyl-3,4-
di-O-benzyl-α-D-mannopyranoside (4-15) 
 
The donor (4-8) and the acceptor (4-14) were dried under high vacuum for 2h. To a stirring 
solution of donor (3.0 g, 4.7 mmol) and acceptor (2.5 g, 5.0 mmol) in anhydrous DCM at -10 oC, 
TMSOTf (85 µL, 0.47 mmol) was added. The reaction mixture was stirred at -10 oC until the donor 
was consumed checking by TLC. NEt3 was added to quench the reaction, and the solvent was 
removed under reduce pressure. The residue was subject to flash column eluting with 
hexane/EtOAc (5:1) to yield the disaccharide 4-15 as a white syrup (4.33 g, 4.42 mmol, 94%). 
Allyl (3,4,6-Tri-O-benzyl-α-D-mannopyranosyl)-(1→6)-2-O-benzoyl-3,4-di-O-benzyl 
-α-D-mannopyranoside (4-16) 
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To a stirring solution of disaccharide 4-15 (4.33g, 4.42 mmol) in MeOH and DCM at 0 oC, 
AcCl (1.6 mL, 22.1 mmol) was added. The reaction mixture was stirred at rt until the starting 
material was comsumed. NEt3 was added to quench the reaction. The solvent was removed under 
reduce pressure and the residue was subjected to column eluting with hexane/EtOAc (3:1) to yield 
disaccharide acceptor 4-16 as an oil (3.73 g, 3.98 mmol, 90%). 
Allyl (2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl) - (1→2)-3,4-di-O-benzyl-
6-O-triisopropylsilyl-α-D-mannopyranoside (4-17) 
 
The donor (4-8) and the acceptor (4-12) were dried under high vacuum for 2h. To a stirring 
solution of donor (3.0 g, 4.7 mmol) and acceptor (2.78 g, 5.0 mmol) in anhydrous DCM at -10 oC, 
TMSOTf (85 µL, 0.47 mmol) was added. The reaction mixture was stirred at -10 oC until the 
donor was consumed checking by TLC. NEt3 was added to quench the reaction, and the solvent 
was removed under reduce pressure. The residue was subject to flash column eluting with 
hexane/EtOAc (5:1) to yield the disaccharide 4-17 as a white syrup (4.36 g, 4.23 mmol, 90%). 
(2-O-Acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-(1→2)-3,4-di-O-benzyl-6-O-
triisopropylsilyl-α-D-mannopyranosyl trichloroacetimidate (4-19) 
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To a stirring solution of disaccharide 4-17 (1.03 g, 1.00 mmol) in HOAc and H2O, NaOAc 
(0.49 g, 6.00 mmol) and PdCl2 (0.26 g, 1.50 mmol) were added. The reaction mixture was stirred 
at rt for 12 h (monitored by TLC). The solution was then filtered through a small silica gel plug 
and quenched with saturated NaHCO3. The aqueous layer was extracted with EtOAc and the 
combined organic layers were washed with brine and dried over Na2SO4. The solvent was removed 
under reduced pressure to yield crude alcohol (0.80 g) which was used for next reaction without 
further purification.  
The crude alcohol (0.80 g, 0.78 mmol) was dissolved in dry DCM and cooled to 0 °C. To 
this solution Cl3CCN (0.40 mL, 4.00 mmol) and DBU (0.03 mL, 0.24 mmol) was added and stirred 
for 1h at rt. The solvent was removed under reduced pressure and the residue was purified by flash 
chromatography (EtOAc/hexane (1:4) to give 6 (0.68 g, 60% for two steps) as a colorless oil.  
Allyl (2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-(12)-(3,4-di-O-benzyl-
6-O-triisopropylsilyl-α-D-mannopyranosyl)-(12)-(3,4,6-tri-O-benzyl-α-D-
mannopyranosyl)-(16)-2-O-benzoyl-3,4-di-O-benzyl-α-D-mannopyranoside (4-20) 
 
A mixture of disaccharide acceptor 4-16 (0.40 g, 0.43 mmol) and mannose donor 4-19 
(0.58 g, 0.51 mmol) was co-evaporated with toluene (3 × 3 mL) and dried under vacuo overnight. 
To a stirring solution of the acceptor and donor in dry DCM at -20 oC, TMSOTf (7.00 µL, 0.04 
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mmol) was added. The reaction mixture was stirred for 1 h at -20 oC and 0.5 h at -10 oC (monitored 
by TLC). The reaction was quenched by the addition of Et3N (0.50 mL) and the reaction mixture 
was concentrated. The crude was purified by chromatography eluting with Hexane/EtOAc (4:1) to 
yield tetrasaccharide 4-19 as a white syrup (0.60 g, 80%). 
(2-O-Acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-(12)-(3,4-di-O-benzyl-6-O-
triisopropylsilyl-α-D-mannopyranosyl)-(12)-(3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-
(16)-2-O-benzoyl-3,4-di-O-benzyl-α-D-mannopyranosyl trichloroacetimidate (4-21) 
 
To a stirring solution of tetrasaccharide 4-20 (0.60 g, 0.31 mmol) in HOAc (0.02 L) and 
H2O (0.80 mL), NaOAc (0.38 g, 4.63 mmol) and PdCl2 (0.41 g, 2.30 mmol) were added and the 
mixture was stirred for 12 h at rt. The solution was then filtered through a small silica gel plug and 
quenched with saturated solution of NaHCO3 and extracted with EtOAc (3 × 0.10 L). The 
combined organic layers were washed with brine and dried over Na2SO4. The solvents were 
evaporated on reduced pressure to obtain the crude alcohol (0.45 g) which was used for next 
reaction without further purification. The crude alcohol (0.45 g, 0.22 mmol) was dried under 
vacuum, dissolved in DCM (0.01 L) and cooled to 0 °C. CCl3CN (0.60 mL, 6.00 mmol) and DBU 
(0.03 mL, 0.24 mmol) was added and stirred at rt for 1 h. The reaction mixture was concentrated 
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on reduced pressure and the resulting crude was purified by chromatography (EtOAc;hexane (1:9)) 
to afford donor 4-21 (0.37 g, 60% over two steps).  
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-D-galactopyranoside (4-24) 
 
To a stirring solution of NaN3 (8.94 g, 137 mmol) in H2O (20 mL) at 0 
oC, DCM (36 mL) 
was added. The mixture was stirred vigorously and Tf2O (4.68 mL, 27.90 mmol) was added, and 
the reaction mixture was stirred at 0 oC for 2h. The organic layer was separated and the aqueous 
layer was extracted with DCM twice. The combined organic layer was washed with saturated 
Na2CO3, which was used without further purification. GlcNH2·HCl (3.0 g, 13.95 mmol) was 
dissolved in H2O and treated with K2CO3 (2.88 g, 20.93 mmol) and CuSO4 (21 mg, 132 µmol). 
MeOH was added followed by careful addition of the fresh made TfN3 solution. More MeOH was 
added to achieve a homogeneous solution and the reaction was stirred for 6 h at rt. The solvent 
was removed under reduced pressure and the residue was re-dissolved in pyridine (75 mL). After 
cooling to 0 oC, Ac2O (45 mL) was added and the reaction mixture was stirred at rt for 2h. The 
solvent was removed under reduced pressure and the residue was redissolved in EtOAc before 
washing with 1N HCl and saturated NaHCO3. After drying with Na2SO4, the residue was subjected 
to flash column to yield compound 4-24 as a white syrup (4.69 g, 90%). 
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-D-galactopyranosyl trichloroacetimidate (4-
26) 
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To a stirring solution of compound 4-24 (4.69 g, 12.56 mmol) in DMF, hydrazine acetate 
(1.27 g, 13.8 mmol) was added. The reaction mixture was stirred at rt for 1 h. Then water and 
EtOAc were added and the layer was separated. The aqueous layer was extracted with EtOAc, and 
the combined organic layers were washed with brine and dried over Na2SO4. After concentrating 
to dryness, the residue was dissolved in anhydrous DCM at 0 oC, followed by the addition of 
CCl3CN (6.3 mL, 62.8 mmol) and DBU (180 µL, 1.2 mmol). The reaction mixture was stirred at 
rt for 2 h. Then the solvent was removed under reduced pressure, and the residue was subjected to 
flash column to yield imidate 4-26 as a white solid (4.18g, 8.8 mmol, 70% over 2 steps). 
Methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside (4-30) 
 
To a stirring solution of methyl-α-D-gluopyranoside (3.66 g, 18.85 mmol) and imidazole 
(3.86 g, 56.55 mmol) in DMF (30 mL), TIPSCl (4.43 mL, 20.70 mmol) was added dropwise over 
a period of 15 minutes. After 24 h at rt, the reaction was diluted with water (100 mL) and extracted 
with DCM (3 x 60 mL). The combined organic layer was washed with brine, dried over Na2SO4, 
concentrated in vacuo, and placed under high vacuum. A solution of this crude product and BnBr 
(11.2 mL, 94.28 mmol) in DMF (100 mL) was cooled to 0 °C and NaH (60% in mineral oil, 3.77 
g, 94.28 mmol) was added. The reaction mixture was allowed to warm to rt. After 12 h at rt, the 
reaction mixture was transferred to a separatory funnel and carefully quenched by minimum 
amount of MeOH and water (100 mL). The reaction mixture was extracted with Et2O (3 x 100 
mL). The combined organic layer was washed with brine, dried over Na2SO4, and concentrated in 
vacuo. The crude product was combined with TBAF·H2O (solid, 12 g, 36.03 mmol) and THF (20 
mL) was added. The reaction solution was stirred at rt for 12 h, diluted with H2O, and extracted 
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with EtOAc (3x). The combined organic layer was washed with brine, dried over Na2SO4, 
concentrated in vacuo, and purified by flash silica column chromatography eluting with 
hexane/EtOAc to obtain the title compound 4-30 as a colorless syrup (7.0 g, 80%, 3 steps). 
Methyl 2,3,4-tri-O-benzyl-6-O-acetyl-5Z-α-D-glucopyranoside (4-32) 
 
To a stirring solution of compound 4-30 (7.0 g, 15.08 mmol) in DCM at 0 °C, SO3·Py (9.6 
g, 60.32 mmol) was added, immediately followed by addition of N, N-diisopropylethylamine 
(DIPEA, 13.8 mL, 105.56 mmol). The reaction mixture was stirred at 0 °C for 10 min and DMSO 
(15.0 mL, 211.12 mmol) was added. After 2 h at 0 °C, the reaction was diluted with saturated 
NaHCO3 and extracted with Et2O. The combined organic layer was washed with brine, dried over 
Na2SO4, concentrated in vacuo, and placed under high vacuum for 4 h. The aldehyde crude 
product was dissolved in MeCN. Then, Ac2O (8.6 mL, 90.48 mmol) and K2CO3 (8.4 g, 
60.32 mmol) were added to the same flask. The reaction mixture was refluxed for 12 h and allowed 
to cool to rt. The reaction mixture was diluted with saturated NaHCO3 and extracted with Et2O. 
The combined organic layer was washed with brine, dried over Na2SO4, concentrated in vacuo, 
and the residue was subjected to flash column eluting with hexane/EtOAc (7:3) to yield the desired 
compound 4-32 as a white syrup (5.94 g, 11.76 mmol, 78%, over 2 steps). 
1-O-Acetyl-3,4,5-tri-O-benzyl-D-myo-inositol (4-33) 
 
To a stirring solution of the acetyl enolate compound 4-32 (5.94 g, 11.76 mmol) in a 
mixture of acetone and water, (CF3COO)2Hg (5.8 g, 12.94 mmol) was added at rt. After 1h, the 
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reaction solution was cooled to 0 °C. To this reaction, aqueous NaOAc (4.4 mL of 3 M, 12.94 
mmol) was added, immediately followed by addition of brine (15 mL). The reaction was allowed 
to slowly warm to rt and stirred at rt for 12h. Then the reaction mixture was diluted with saturated 
NaHCO3 and extracted with Et2O. The combined organic layer was washed with brine, dried over 
Na2SO4, concentrated in vacuo, and the residue was subjected to flash column eluting with 
hexane/EtOAc (4:1) to yield the titled compound 4-33 as a white syrup (3.24 g, 6.60 mmol, 56%).  
 
1-O-Acetyl-3,4,5-tri-O-benzyl-D-myo-inositol (4-34) 
 
To a stirring solution of coumpound 4-33 in MeCN at 0 oC, NaBH(OAc)3 (7.0 g, 33.0 
mmol) in a mixture of and MeCN was added dropwise. The reaction mixture was allowed to warm 
to rt and stirred at rt for 12h. Then the reaction mixture was diluted with saturated NaHCO3 and 
extracted with Et2O. The combined organic layer was washed with brine, dried over Na2SO4, 
concentrated in vacuo, and purified by flash silica column eluting with hexane/EtOAc (1:1) to 
yield the compound 4-34 as a colorless syrup (2.67 g, 5.4 mmol). 
1-O-Allyl-3,4,5-tri-O-benzyl-D-myo-inositol (4-35) 
 
To a stirring solution of inositol 4-34 (6.6 g, 13.4 mmol) and ethyl vinyl ether (26 mL, 0.27 
mol) in DCM at rt, PPTS (0.52 g, 2.0 mmol) was added. The reaction mixture was stirred for 12 h 
and the solvents were removed in vacuo. The residue was then dissolved in MeOH and NaOMe 
(11 mg, 0.2 mmol) was added. The reaction mixture was heated to 50 °C and stirred for 5 h. The 
solvents were then removed in vacuo and the residue was filtered through a pad of silica gel (eluent 
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DCM:MeOH= 20:1) and the filtrate was evaporated to dryness. The crude residue at this stage was 
dissolved in DMF. Allyl bromide (5.8 mL, 67 mmol) and TBAI (0.5 g, 1.36 mmol) were then 
added in and the reaction mixture was cooled to 0 °C. NaH (3.0 g, 75.0 mmol, 60% in mineral oil) 
was added portionwise and the mixture 
was stirred for 12 h while warmed up to room temperature. The mixture was then diluted 
with THF and 2N HCl (50 mL) was added slowly. Upon the completion of the addition, the 
reaction muixture was heated to 50 °C for 2 h. The reaction was then quenched with saturated 
NaHCO3 solution and extracted with EtOAc. The combined organic layers were then washed with 
brine, the solvents removed in vacuo and the residue was purified by silica gel column 
chromatography to give 4-35 (5.3 g, 80%) as a white solid. 
1-O-Allyl-3,4,5-tri-O-benzyl-2-O-(4-methoxybenzyl)-D-myo-inositol (4-36) 
 
To a stirring solution of inositol 4-35 (0.485 g, 0.99 mmol) and TBAI (0.361 g, 0.99 mmol) 
in DMF at 0 ºC, NaH (60% in mineral oil, 0.131 g, 2.97 mmol) was added. After 30 min stirring 
at 0 ºC, the reaction mixture was cooled to –20 ºC using an ice/acetone bath. Then, p-
methoxybenzyl chloride (161 µL, 1.19 mmol) in DMF was added dropwise. The reaction was 
stirred at rt for 3 h, then the reaction was quenched with water, and extracted by Et2O. The 
combined organic layers were further washed with water, brine, and dried over Na2SO4. The 
solvent was removed in vacuo, and the residue was purified by flash silica column chromatography 
eluting with hexane/EtOAc (7:3) to yield compound 4-36 (0.415 g, 68%) as an off-white solid. 
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(2-Azido-2-deoxy-D-glucopyranosyl)-(1→6)-1-O-allyl-2,3,4,5-tetra-O-benzyl-D-myo-
inositol (4-38) 
 
Glucosamine trichloroacetimidate 4-26 (316 mg, 0.664 mmol) and inositol 4-36 (270 mg, 
0.442 mmol) were co-evaporated with toluene and subsequently dried under high vacuum for 2 h, 
then dissolved in dry DCM and cooled to -30 ºC. Freshly-made TMSOTf solution in DCM (0.125 
M, 400 mL, 50 mmol) was added. The reaction mixture was stirred at -30 ~ -20 ºC for 30 mins 
and quenched with Et3N. The solvent was evaporated in vacuo, and the residue was dissolved in 
MeOH and DCM, NaOMe (0.5 M in MeOH, 0.6 mL, 0.3 mmol) was added at rt. After further 
stirring for 3 h at 40 °C, the solution was neutralized with acidic DOWEX resin at rt to 
approximately pH 6, filtered and evaporated to give the crude product, which was purified by flash 
silica column chromatography afforded a diastereomeric mixture of 4-38 (314 mg, 89%, α:β=3:1) 
as an white foam. 
2-azido-2-deoxy-3-O-benzyl-4,6-O-benzylidene-D-glucopyranosyl)-(1→6)-1- 
O-allyl-2,3,4,5-tetra-O-benzyl-D-myo-inositol (4-40) 
 
To a stirring solution of the disaccharide 4-38 (1.08 g, 1.35 mmol) in CH3CN, 
benzaldehyde dimethyl acetal (553 µL, 4.05 mmol) and (+)-Camphorsulfonic acid 
(CSA) (31.3 mg, 13.5 mmol) were added at rt. The reaction mixture was stirred for 3 h, 
before being quenched with Et3N. The solvent was then evaporated under reduced pressure. The 
residue was co-evaporated with toluene (3 x 5 mL) and dried under high vacuum for 1 h. The 
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residue was then dissolved in DMF, followed by the addition of tetrabutylammoium iodide (757 
mg, 2.02 mmol). The reaction mixture was cooled to 0 ºC and NaH (60% in mineral oil, 115 mg, 
2.7 mmol) was added. After 20 min, BnBr (240 µL, 2.02 mmol) was added. Within 6 h, the reaction 
mixture was warmed to ambient temperature and quenched with water. The aqueous layer was 
extracted with EtOAc and the combined organic layers were further washed with water and brine. 
Evaporation in vacuo led to the crude product, which was purified by a flash silica gel column 
eluting with hexane/EtOAc (5:1) to give compound 4-40 (0.98 g, 74%) as a white foam. 
(2-Azido-2-deoxy-3,6-di-O-benzyl--D-glucopyranosyl)-(1→6)-1-O-allyl-2,3,4,5-
tetra-O-benzyl-D-myo-inositol (4-41) 
 
To a stirring solution of disaccharide 4-40 (980 mg, 1.01 mmol) in THF, NaCNBH3 (1.0 
M in THF, 10 mL, 10 mmol) was added and the solution was cooled to 0 ºC. Under a stream of 
argon gas, HCl in Et2O (2.0 M) was added portion by portion until the reaction mixture reached 
PH 1. The reaction mixture was then warmed up to rt, and allowed to stir further for 1 h before 
addition of saturated aqueous NaHCO3 solution. The aqueous layer was extracted with EtOAc. 
The combined organic layers were further washed with saturated aqueous NaHCO3 solution and 
brine, and evaporated to dryness in vacuo. The residue was subjected to flash silica gel column to 
give desired a-isomer 7 (426 mg, 43%) as a colorless syrup. 
(2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl)-(1→2)-(3,4-di-O-benzyl-6-O-
triisopropylsilyl--D-mannopyranosyl)-(1→2)-(3,4,6-tri-O-benzyl--D-mannopyranosyl)-
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(1→6)-(2-O-benzoyl-3,4-di-O-benzyl--D-mannopyranosyl)-(1→4)-(2-azido-2-deoxy-3,6-di-
O-benzyl--D-glucopyranosyl)-(1→6)-1-O-allyl-2,3,4,5-tetra-O-benzyl-D-myo-inositol (4-42) 
 
 Tetramannoside donor 4-21 (96 mg, 0.048 mmol) and disaccharide acceptor 4-41 (42 mg, 
0.043 mmol) were mixed, and co-evaporated with toluene, and dried under high vacuum overnight. 
They were then dissolved in DCM and cooled to -40 ºC. TMSOTf (7.8 µL, 42.9 µmol) was added. 
The reaction mixture was allowed to stir at -40 ºC for 1 h before being quenched with Et3N. The 
solvent was evaporated in vacuo. The residue was subjected to flash column chromatography 
eluting with hexane/EtOAc (4:1) to afford the titled compound (86 mg, 70%) as a white foam. 1H 
NMR (400 MHz, CDCl3, δ): 8.11 (d, J = 6.6 Hz, 2H), 7.65−6.92 (m, 85H), 6.16−5.99 (m, 1H, O-
allyl CH), 5.94−5.78 (m, 2H, anomeric H), 5.78−5.60 (m, 2H, anomeric H), 5.55−5.28 (m, 3H), 
5.27−5.13 (m, 2H), 5.11−3.26 (m, 66H), 2.24 (s, 3H), 1.16 (s, 21H); 13C NMR (100 MHz, CDCl3) 
δ 170.2, 165.4, 139.0, 138.9, 138.7, 138.6, 138.5, 138.3, 138.0, 137.8, 137.5, 134.4, 133.2, 130.1, 
129.9, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.6, 127.6, 127.4, 127.2, 127.1, 117.2, 
100.1, 100.0, 99.2, 99.1, 97.7, 82.1, 81.9, 81.4, 81.0, 80.6, 78.0, 79.7, 78.8, 75.9, 75.6, 75.4, 75.2, 
74.6, 74.5, 74.2, 73.6, 73.5, 73.3, 73.0, 72.7, 72.3, 72.1, 71.9, 71.7, 71.3, 70.9, 69.7, 69.1, 68.9, 
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68.5, 66.3, 63.7, 29.8, 21.3, 18.3, 12.1 ppm. HRMS ESI (m/z): [M + Na]+ calcd for 
C169H187N3NaO32Si, 2821.2765; found, 2821.2712. 
(2,3,4,6-Tetra-O-benzyl--D-mannopyranosyl)-(1→2)-(3,4-di-O-benzyl-6-O-
triisopropylsilyl--D-mannopyranosyl)-(1→2)-(3,4,6-tri-O-benzyl--D-mannopyranosyl)-
(1→6)-(2,3,4-tri-O-benzyl--D-mannopyranosyl)-(1→4)-(2-azido-2-deoxy-3,6-di-O-benzyl-
-D-glucopyranosyl)-(1→6)-1-O-allyl-2,3,4,5-tetra-O-benzyl-D-myo-inositol (4-44) 
 
To a stirring solution of hexasaccharide 4-42 (115 mg, 0.043 mmol) in DCM and MeOH, 
NaOMe (30%, 0.6 mL, 0.3 mmol) was added at rt. The reaction mixture was then heated to 50 ºC 
and stirred at this temperature for 20 h. After cooling down, the reaction mixture was carefully 
neutralized with acidic DOWEX resin to approximately PH 6. The resin was removed by filtration 
and the filtrate was evaporated to dryness. The residue was put on high vacuum for 2h and then 
redissolved in DMF and cooled to 0 ºC. NaH (60% in mineral oil, 6.4 mg, 0.20 mmol) was added. 
After stirring for 30 min, BnBr (24 µL, 0.2 mmol) was added. The reaction was allowed to warm 
up to ambient temperature and stirred for 10 h before being quenched with water. The mixture was 
extracted with EtOAc and the combined organic phase was further washed with water and dried 
over Na2SO4. Evaporation in vacuo gave the residue which was further purified by flash silica gel 
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column eluting with hexane/EtOAc (4:1) to give 4-44 (67 mg, 70%) as a white foam. 1H NMR 
(400 MHz, CDCl3) δ: 7.64−6.95 (m, 92H), 6.09−5.91 (m, 1H), 5.85 (d, J = 3.1 Hz, 1H), 5.45−5.20 
(m, 5H), 5.16−3.24 (m, 73H), 1.10 (d, J = 4.9 Hz, 21H) ppm. 13C NMR (100 MHz, CDCl3) δ: 
138.8, 138.6, 138.5, 138.4, 138.0, 134.3, 128.5, 128.4, 128.3, 128.2, 128.2, 128.1, 127.9, 127.8, 
127.7, 127.5, 127.5, 127.4, 127.2, 127.1, 126.9, 117.2, 100.5, 100.3, 99.7, 99.2, 97.4, 82.0, 81.5, 
80.9, 80.5, 80.2, 80.1, 80.0, 79.9, 76.1, 75.9, 75.1, 74.8, 73.4, 73.2, 72.2, 72.1, 71.6, 71.5, 71.3, 
70.9, 69.7, 69.0, 68.9, 68.8, 68.7, 63.3, 62.6, 18.2, 12.0 ppm. HRMS ESI (m/z): [M + Na]+ calcd 
for C174H193N3O30NaSi, 2832.3438; found, 2832.3467. 
(2,3,4,6-Tetra-O-benzyl--D-mannopyranosyl)-(1→2)-(3,4-di-O--D-
mannopyranosyl)-(1→2)-(3,4,6-tri-O-benzyl--D-mannopyranosyl)-(1→6)-(2,3,4-tri-O-
benzyl--D-mannopyranosyl)-(1→4)-(2-azido-2-deoxy-3,6-di-O-benzyl--D-
glucopyranosyl)-(1→6)-1-O-allyl-2,3,4,5-tetra-O-benzyl-D-myo-inositol (4-45) 
 
To a solution of 4-44 (0.110 g, 0.046 mmol) in DCM (4 mL) and MeOH (1 mL), AcCl 
(0.03 mL, 0.46 mmol) and stirred at rt for 2 h. Reaction mixture was diluted with DCM (50 mL) 
and washed with aq. NaHCO3 solution, brine. The organic layer was dried over anhydrous sodium 
sulfate, evaporated under reduced pressure and the residue was purified by column 
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chromatography eluting with hexane/EtOAc (4:1) to give 4-45 (0.095 g, 91%). 1H NMR (400 
MHz, CDCl3) δ: 7.52−6.97 (m, 92H), 6.04−5.89 (m, 1H), 5.79 (d, J = 3.6 Hz, 1H), 5.37−5.18 (m, 
4H), 5.13 (s, 1H), 5.04 (d, J = 11.2 Hz, 1H), 4.92−4.89 (m, 9H), 4.82−4.72 (m, 3H), 4.60−4.55 (m, 
16H), 4.43−4.25 (m, 7H), 4.23−3.96 (m, 10H), 3.96−3.32 (m, 26H), 3.26 (dd, J = 16.3, 6.5 Hz, 
2H). 13C NMR (100 MHz, CDCl3) δ: 138.9, 138.6, 138.1, 134.3, 128.5, 128.3, 128.2, 128.1, 127.9, 
127.8, 127.7, 127.5, 127.2, 127.1, 126.9, 117.3, 100.7, 100.2, 99.0, 97.4, 81.9, 81.4, 81.0, 80.1, 
78.0, 79.5, 78.9, 76.3, 76.0, 75.4, 75.1, 75.0, 74.7, 74.4, 74.1, 73.8, 73.3, 73.2, 72.8, 72.7, 72.7, 
72.4, 72.3, 72.0, 71.9, 71.4, 71.0, 69.7, 68.9, 68.4, 66.1, 63.3, 62.0 ppm. HRMS ESI (m/z): [M + 
Na]+ calcd for C165H173N3O30Na, 2699.2002; found, 2699.2052. 
(2,3,4,6-Tetra-O-benzyl-α-D-mannopyranosyl)-(1→2)-(3,4-di-O-benzyl-6-O-(2-(N-
benzyloxycarbonyl)aminoethyl-phosphonato-α-D-mannopyranosyl)-(1→2)-(3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-(1→6)-(2,3,4-tri-O-benzyl-α-D-mannopyranosyl)-(1→4)-(2-
azido-2-deoxy-3,6-di-O-benzyl-α-D-glucopyranosyl)-(1→6)-1-O-allyl-2,3,4,5-tetra-O-benzyl-
D-myo-inositol (4-46) 
 
Ethanolamine H-phosphonate (144 mg, 0.40 mmol) and hexasaccharide 4-45 (90 mg, 0.040 
mmol) were co-evaporated with anhydrous pyridine (3 × 3 mL) in two separate portions of 10 mL 
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of round bottom flask and dried under high vacuum overnight. The ethanolamine H-phosphonate 
was dissolved in anhydrous pyridine (1 mL) followed by the addition of pivaloyl chloride (50 µL, 
0.40 mmol) stirring for 15 min at rt. To that mixture, a solution of hexasaccharide 4-45 in 
anhydrous pyridine (1.5 mL) was added, and the resulting mixture was stirred at rt for 12 h. Iodine 
(100 mg, 0.40 mmol) in a mixture of pyridine and water (19:1, 0.5 mL) was added to oxidize P(III) 
to P(V) and stirred for additional 6 h at rt. The reaction mixture was diluted with DCM (50 mL) 
and the organic layer was washed with sodium thiosulfate solution, followed by 100 mM TEAB 
(triethylammonium borate) buffer solution, and dried over anhydrous sodium sulfate. The solvents 
were evaporated on reduced pressure, and the crude was purified by flash column chromatography 
with Et3N deactivated silica gel to give 4-46 (92 mg, 92%) as a gummy liquid. 1H NMR (400 
MHz, CDCl3) δ: 7.84 (s, 4H), 7.52−6.85 (m, 93H), 6.00−5.87 (m, 1H), 5.76 (s, 1H), 5.62 (s, 1H), 
5.39−5.08 (m, 4H), 5.08−2.99 (m, 80H). 13C NMR (100 MHz, CDCl3) δ: 144.9, 141.7, 139.0, 
138.8, 138.5, 138.3, 137.9, 134.2, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.7, 127.5, 127.4, 
127.1, 127.0, 117.3, 100.2, 99.0, 97.4, 96.1, 81.9, 81.5, 80.9, 79.5, 79.1, 75.8, 75.5, 75.2, 75.0, 
74.4, 74.1, 73.9, 73.3, 73.2, 72.8, 72.4, 72.2, 72.1, 71.8, 71.7, 71.4, 70.9, 69.7, 68.9, 66.6, 66.2, 
63.2 ppm. 31P NMR (162 MHz, CDCl3, δ): −0.26 ppm. HRMS ESI (m/z): [M−H]
+ calcd for 
C175H184N3O35P, 2932.2479; found, 2932.2490 
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α-D-Mannopyranosyl-(1→2)-(6-O-aminoethyl-phosphonato)-α-D-mannopyranosyl-
(1→2)-α-D-mannopyranosyl-(1→6)-α-D-mannopyranosyl-(1→4)-(2-amino-2-deoxy-α-
Dglucopyranosyl)-(1→6)-1-O-propyl-D-myo-inositol(4-47).  
 
Phosphorylated hexasaccharide 4-46 (90 mg, 0.035 mmol) was dissolved in a mixture of 
MeOH (2 mL) and formic acid (5 μL) followed by Pd(OH)2/C (20% Pd content) (20 mg), and the 
mixture was purged with nitrogen. The mixture was then stirred in an atmosphere of hydrogen 
(hydrogen balloon pressure) for 12 h. The reaction mixture was filtered through a fret filter with 
methanol (10 mL). Solvents were evaporated with reduced pressure and dried under high vacuum. 
The 1H NMR of the crude shows the complete conversion of the starting material to product. The 
product was passed through the biogel P2-column and lyophilized to give the pseudo-GPI anchor 
3 as a white solid (35 mg, 94%). 1H NMR (400 MHz, D2O) δ: 5.28 (s, 1H), 5.21 (s, 1H), 5.16 (s, 
1H), 5.02 (s, 1H), 4.97 (s, 1H), 4.23 (s, 1H), 4.04 (s, 4H), 3.99 (s, 2H), 3.94−3.85 (m, 4H), 
3.83−3.30 (m, 28H), 3.21 (s, 2H), 3.13−3.06 (m, 1H), 1.60−1.48 (m, 2H), 0.82 (t, J = 7.4 Hz, 3H) 
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ppm. 31P NMR (162 MHz, CDCl3) δ: −0.26 ppm. HRMS ESI (m/z): [M − H]+ calcd for 
C41H74N2O33P, 1153.3911; found, 1153.3982. 
4.4.2 Conjugation of Glycans (1, 2, and 3) with Activated KLH. 
GPI−KLH conjugates (GPI1, GPI2, and GPI3) were synthesized from 1, 2, and 3 by using 
an Imm-Link KLH (Amine) Immunogen labeling Kit and Conjugation Protocol provided by 
Novobios (http://www.novusbio.com/Imm-Link- KLH-(Amine)-Kit_450-0500.html). Briefly, 2 
mg of Imm-Link KLH (molecular weight of ∼400 kDa; 0.0050 μmol, 1 equiv) was reacted with 1 
mg glycan 1, 2, or 3 (∼200 equiv). Glycan 1, 2, or 3 (1 mg) dissolved in 10 mM phosphate buffer 
(1 mL) and 50 μL of amine modifier provided by the manufacturer was added at rt. After 10 min, 
the solution was added to the vial containing preactivated KLH (2 mg) and stirred at rt for 12 h. 
The solution was transferred to dialysis cassettes with a cutoff 
of 7000 Da and dialyzed against distilled water three times to remove unreacted material 
and impurities. After lyophilization, the final conjugates (GPI1 (1.90 mg), GPI2 (1.82 mg), and 
GPI3 (1.98 mg)) were obtained as white solids. The glycoconjugates were analyzed by phenol-
sulfuric acid assay method. 
4.4.3 Rabbit Immune Sera Preparation.  
A total of six rabbits were immunized with the three synthetic GPIs (rabbits 1 and 2 were 
immunized with GPI1, rabbits 3 and 4 with GPI2, rabbits 5 and 6 with GPI3), according to a 
standard 70 day rabbit immunization protocol (Thermo Scientific). The primary injection was 
carried out on day 1, and 0.5 mg of antigen was injected; subsequently, three booster injections 
with 0.25 mg of antigen were given on day 14, day 28, and day 42, respectively. The titer of elicited 
anti-GPI antibodies from rabbit sera at various bleeding time points (I: before immunization; II: 7 
days after the first injection; III: 7 days after the second injection; IV: 7 days after the third 
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injection; and V: 14 days after the fourth injection) were measured using Luminex assay, which is 
a color-coded bead-based binding assay. Briefly, antigen-coated beads were incubated with rabbit 
sera, and the bounded rabbit IgG was detected by a complex of biotinylated anti-rabbit IgG and 
phycoerythrin (PE)-conjugated streptavidin. 
4.4.4 Luminex Assay.  
GPI analogues 1, 2, and 3 were coupled to carboxylated MagPlex microspheres (Luminex 
Corporation). The coated beads were incubated with rabbit sera at a 1:1000 dilution at room 
temperature for 1 h and washed three times with phosphate buffer saline containing 0.5% Tween-
20 (PBST). The beads then were incubated with biotinylated goat anti-rabbit IgG (0.5 μg/mL, 
SouthernBiotech) at room temperature for 45 min and washed three times with PBST. Next, the 
beads were incubated with streptavidin phycoerythrin (2 μg/mL, Life Technologies) at room 
temperature for 30 min followed by three washes with PBST. The fluorescence intensity of beads 
were measured and recorded by a Bio-Plex MAGPIX Multiplex Reader. The fluorescence intensity 
shown in Figure 4-6 is the mean value of 50 beads after subtracting the background. 
4.4.5 ELISA.  
Anti-KLH antibodies were removed from the total IgG by solid-phase immunoaffinity 
column chromatography over a KLH- Separopore 4B to enrich for GPI-specific antibodies. The 
purified anti-GPI antibodies were used in the ELISA assay to determine the elicited response to 
native plasmodium GPI. P. falciparum GPIs, kindly given by Dr. D. Channe Gowda, were 
extracted from natural P. falciparum parasites and purified by HPLC. GPIs were dissolved in 
methanol to yield a coating solution of 40 ng/mL. A total of 50 μL of coating solution was added 
to each well, and the plate was dried in incubator at 37 °C overnight. The wells were washed once 
with 100 μL of PBST and blocked with PBS−casein (pH7.4, 0.5% casein) for 1 h at rt. A total of 
112 
50 μL of diluted sera samples (1:10) in PBS−casein, containing 0.05% Tween 20, was added to 
the wells and incubated for 1 h at rt. The wells were washed three times with PBST, and 50 μL of 
poly-HRP conjugated goat anti-rabbit antibodies (1:200 dilution in PBS−casein) was added to each 
well. After 1 h of incubation at rt, the wells were washed three times with 100 μL of PBST. 50 μL 
of TMB peroxidase substrate solution (KPL) was added to each well and incubated at rt for 1 h. A 
total of 50 μL of 1 M sulfuric acid was added to quench the reaction, and absorbance at 405 nm 
was measured. Each sample was assayed in triplicate. The control human hyperimmune serum was 
obtained from a previous study carried out in Kenya,33 which was pooled from samples of patients 
with multiple exposures to P. falciparum infection. 
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5 CHAPTER 5. TETRAZINE-TRANSCYCLOOCTENE (TCO) PAIRS BASED 
BIORTHOGONAL AMPLIFICATION 
5.1 Introduction 
Bioorthogonal chemistry refers to any chemical reaction that can occur inside of living 
systems without interfering with native biochemical processes, which was first pointed out by 
Carolyn R. Bertozzi131. To date, more than 20 different bioorthogonal reactions have been 
discovered132,133,134. Among them, the most famous reaction is “click reaction”, also known as the 
Cu(I)-catalysed [3+2] azido–alkyne cycloaddition (CuAAC) between an azide and alkyne (Figure 
5.1)135,136, which was discovered independently by Sharpless et al. and Meldal et al. Now, this 
click reaction is widely used in the biological lab for different purpose, such as labeling and 
imaging the live cells. However, this click reaction is limited in living cells due to the potential 
toxicity of Cu. In fact, Bertozzi et al. reported that mammalian cells could only survive with low 
concentrations (<500 µM) of Cu(I), which leads to very slow CuAAC reaction rates134. To 
overcome the limitations of CuAAC reactions, the water-soluble Cu(I) ligands and strained alkyne 
substrates were used to replace the role of Cu(I)137,138. The strain-promoted [3+2] azide–alkyne 
cycloaddition (SPAAC) was discovered by Bertozzi et al. in 2004139, which can work in 
physiological conditions without any catalyst. However, the rate constant is slower compared to 
that with CuAAC (typically 10-2 to 1 M-1S-1 compared to 10~100 M-1S-1 for CuAAC). 
Besides CuAAC, several biorthogonal reactions, such as Stauginger ligation140 and 
SPANC cycloaddition between nitrones and alkynes141 have been developed. However, these 
reactions are mainly used in vitro now. Until 2008, IEDDA reaction between tetrazines and 
strained dienophiles was discovered by Fox group142, which is the fastest bioorthogonal reaction 
developed to date and can be used in vivo. The reaction constant of IEDDA reaction can reach to 
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104 M-1s-1, which is extremely faster than others. IEDDA reaction is highly selective, is mild 
reaction in H2O and has the fastest kinetic rate. Due to all the features, IEDDA reaction is a really 
good candidate of bioorthogonal chemistry. 
 
Figure 5-1 The bioorthogonal reaction discovered to date and its rate 
constant143,144,145,146,147.  
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5.2 IEDDA reaction Mechanism 
In a normal Diels-Alder reaction, an electron-rich diene reacts with an electron-poor 
dienophile to yield the conjugate product. However, in an inverse-electron-demand Diels–Alder 
reaction (IEDDA), an electron-rich dienophile reacts with an electron poor diene. The mechanism 
of tetrazine ligation was shown in Figure 5-2. Briefly, tetrazine reacts dienophile to form 4+2 
intermediate. After releasing a molecule of nitrogen gas, a retro Diels-Alder reaction happens to 
form 4,5-dihydropyridazine. This molecule can either isomerises to the corresponding 1,4-
dihydro-isomers or is oxidized to give a pyridazine product (Figure 5-2).  
 
Figure 5-2 The mechanism of IEDDA reaction. 
The substituent group on tetrazine affect the reaction rate. Tetrazines with electron 
donating group react with dienophile slowly. In contrast, electron withdrawing group will 
accelerate the reaction. 
5.3 IEDDA triggered ‘‘click-to-release’’ of TCO bearing molecules. 
In 2013, Robillard et al. demonstrated that the superfast IEDDA reaction could serve as a 
cleavage reaction for drug release and activation148. By reacting a doxorubicin carbamate-linked 
TCO derivative with tetrazine, the resulting 1,4-dihydropyridazine product could undergo 
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elimination of doxorubicin and CO2 if TCO is modified at the allylic position. Notably, it was 
shown that the axially substituted TCO presents 156-fold higher reactivity than equatorial 
corresponding isomer, which presumably derives from the steric interaction between tetrazine and 
equatorial benzyl carbamate moiety.  The mechanism of the click to release reaction is shown in 
Figure 5-3. Briefly, tetrazine and TCO undergoes Diels-Alder reaction and retro-Diels-Alder 
reaction to form 4,5-dihydropyridazine. This molecular can either isomerises to 1,4-
dihydropyridazine or 2,5-dihydropyridazine. The 2,5-isomers lead to a dead-end of the reaction, 
which contribute to ~70% yield of the release. The 1,4-isomer undergoes elimination of CO2 and 
release the drug. 
 
Figure 5-3 The mechanism of IEDDA triggered click to release reaction. 
Later on in 2014, Chen’s group applied the click to release reaction in protein decaging in 
living cells 149. The reaction between axial isomer and caged protein could be finished within in 
minutes. In 2016, the same bioorthogonal strategy was used to activate kinases in living systems150. 
Up to date, a series of click to release research have been published based on the same 
bioorthogonal strategy151,152,153,154,155. 
Recently, Wessleder and coworkers investigated the mechanistic features of this click to 
release reaction and designed acid-functionalized tetrazine156. Utilizing these acidic tetrazines, the 
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release reaction could be finished within minutes and almost yield ~100% release. They also found 
that methylation of nitrogen could also lead to quantitative release. 
Very recently, Robillard and coworkers have expanded the reaction not only carbamate 
linkage, but also carbonate, ester and ether linkage157. They demonstrated that the elimination is 
mainly governed by the formation of the 1,4-dihydropyridazine, and lese by the nature of the 
leaving group. The strategy was used to chemically control cell growth in tyrosine-free medium 
by caging TCO-masked tyrosine.  
Besides the click and release study between tetrazine and TCO derivatives, Bernardes and 
coworkers have demonstrated that tetrazine could react with vinyl ether to release alcohol in 
cells158. 
The electron properties of the substituents of tetrazines are essential for the efficiency of 
the decaging process. By screening a range of tetrazines, it was found that EDG substituted 
tetrazines led to poor decaging due to slow cycloaddition. On the other hand, EWG accelerates the 
elimination step by trapping the cycloaddition intermediate. Notably, two pyrimidine substituted 
tetrazines showed excellent yields and very fast decaging efficiencies in vitro and in live cells155. 
More than 90% decaging occurred after 5 min whereas the previously used dimethyl tetrazine gave 
only 58% decaged yield.  
5.4 Results and discussions 
Based on the literature, we have designed a tetrazine-transcyclooctene based bioorthogonal 
amplification, which is shown in Figure 5-4.  
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Figure 5-4 The designed amplification cycle based on tetrazine ligation. 
Briefly, the initiator is cleaved by the enzyme to release dihydrotetrazine. This species can 
be easily oxidized to tetrazine when exposed to air or by the methylene blue and 660 nm LED 
light159. Then tetrazine can react with amplifier, which is TCO linked to three different reduced 
tetrazine by a scaffold and self-immolative linker, to release three dihydrotetrazine, which can be 
further oxidized to tetrazine. The new generated three tetrazines will react with amplifier again to 
produce nine tetrazine. After several cycles, there will be 3n (n is the number of cycles) tetrazines 
in the solution. Finally, all the tetrazines will react with reporter to release paracetamol, which can 
be picked up by glucose meters. Through this designed amplification cycle, the small signal is 
amplified to a large output in a short time. 
Several reaction rate constant need to be considered in this amplification cycle (Figure 5-
5). Basically, we want the enzyme cleavage rate (k1) is the rate determining step. K2 is the electron 
flowing rate and cyclization, and the latter might be slow. The oxidization rate of dihydrotetrazine 
to tetrazine is k3, which can be made fast by using methylene blue and 660 nm LED light. K4 is 
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Diels-Alder reaction rate of tetrazine and TCO, which is really fast. K5 is release rate from the 
allyl position of TCO and k6 is similar to k4 and k5. In all the different rate constant, k2, k3 and 
k5 are rates need to be considered. 
 
Figure 5-5 The reaction rate constant of each step. 
In our first study, we investigated the oxidization rate of different dihydrotetrazine, ranging 
from electron donating and electron withdrawing substituent of symmetric and asymmetric 
dihydrotetrazine. The results are shown in Table 5-1 and Figure 5-6. From Table, we can conclude 
that dihydrotetrazine which has electron withdrawing group is more stable than electron donating 
group when they are exposed to air. For example, 2,5-dimethyl-1,4-dihydrotetrazine is extremely 
unstable, it is oxidized to the aromatic form when it is synthesized. In contrast, 2,5-dipyridinal-
1,4-dihydrotetrazine is very stable, which can be stored in air for days. All the oxidization rate can 
be accelerated by utilizing methylene blue and 660 nm LED light. 
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Table 5-1Oxidization rate study of different dihydrotetrazine 
 
Different dihydrotetrazine in DMSO/H2O were exposed to air or shined with LED. The 
oxidization rate was determined by measuring the absorbance spectrum. 
 
 
Figure 5-6 The oxidization curve of different tetrazines. The y-axis represents the 
percentage oxidized measuring by absorbance spectrum. The x-axis represents time. 
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Next set of work is designed to evaluate the release rate constant (Figure 5-7). Equatorial 
and axial forms of TCO-coumarin derivatives were synthesized. After reacting with different 
tetrazines including dimethyl, diphenyl and dipyridinal tetrazines, the released coumarin 
concentration was measured by fluorescence meter. It is obvious that the axial form derivative 
released more coumarin than the equatorial form, which is consistent with the literature and 
suggest that axial form should be used in all the experiments. Among different tetrazines, 
dimethyltetrazine release the most. It is reported that one electron withdrawing and one non-
electron withdrawing group is necessary to yield better click to release. 
 
 
Figure 5-7 The release study by using axial or equatorial TCO derivatives and different 
tetrazines. Top: the reaction. Bottom: the releasing curve. The solid line represents axial TCO 
and dot line represents the equatorial TCO. 
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However, the release yield is still not comparable to the reported. Chen’s group reported 
that the release reaction could be finished within 1 h and the yield is ~ 80% for diphenyltetrazine. 
We also found self-quenching occurred, which suggests that measuring the fluorescence might be 
not a good idea. Therefore, we decided to use HPLC for our study, although it requires a lot of 
time. From the HPLC data, the release yield increased a lot compared to fluorescence study (Figure 
5-8). For example, the yield using fluorescence less than 5% using axial-TCO and 
diphenyltetrazine in 1 h. However, the yield increased to 65% using the same reactants when 
measured by HPLC. Encouraged by this data, we used HPLC for all our left experiments. 
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Figure 5-8 The release study measured by HPLC. Top: the release study of axial TCO 
derivative with dimethyl or diphenyl tetrazine within 24 h. Bottom: the expand curve within 2 h. 
To show proof-of-concept and also avoid of the solubility problem, we designed our first 
generation of amplification scheme, shown in Figure 5-9. Compared to the former cycle, simple 
silyl group replaced galactose moiety. And only two reduced form of tetrazines were installed in 
the amplifier. Instead of measuring the paracetamol, we decided to measure the amount of tetrazine 
using HPLC. 
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Figure 5-9 The new designed amplification cycle. 
According to the new amplification scheme, two molecules are required to be synthesized 
(Figure 5-10). One is the initiator, which is tert-butyl-dimethylsilyl (TBS) protected 4-hydroxyl 
benzyl alcohol attached to dihydrotetrazine through a self-immotative spacer. The other one is 
amplification molecule, which itself is also the reporter molecule at the same. The structures of 
these two molecules are shown below. 
 
Figure 5-10 The structures of initiator and amplifier. 
The synthesis of initiator is shown in Scheme 5-1. Briefly, 2,5-diphenyl-2,3-
dihydrotetrazine was synthesized by reacting benzonitrile with anhydrous hydrazine catalyzed by 
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zinc trifluoromethanesulfonate Zn(OTf)2 at 65 
oC overnight.  The crude dihydrotetraizne 5-1 was 
converted into active ester 5-2 by reacting with sodium hydride, 4-nitrophenyl chloroformate in 
THF without further purification. The yield of this step is only ~50% due to the stability of the 
dihydrotetrazine. Boc protected N, N-dimethylethylenediamine was coupled to the tetrazine active 
ester 5-2 to yield the conjugate compound 5-3. After boc deprotection at 0 oC, the free amine 
compound 5-4 was obtained.  
Starting from 4-hydroxylbenzaldehyde, first protect hydroxyl group using TBS under 
TBSCl, imidazole in DMF to yield compound 5-5. Then aldehyde was reduced to primary alcohol 
using sodium borohydride (NaBH4) to yield compound 5-6, which is further converted to the active 
ester 5-7. Couple the amine 5-4 and active ester 5-7 using DIPEA in DMF, the initiator was yielded 
with 66% over 2 steps. 
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Scheme 5-1. The synthesis of initiator. 
To synthesize the appropriate scaffold 5-11, 2,4-dimethyl-1-nitrobenene was oxidized to 
the corresponding carboxylic acid 5-8 by refluxing with KMnO4 in H2O. Then the carboxylic acid 
was reduced to primary alcohol using BH3 in THF to yield compound 5-9. After TBS protection 
and hydrogenolysis in THF-MeOH, the scaffold 5-11 was obtained as shown in Scheme 5-2. 
 
Scheme 5-2. The synthesis of the scaffold 5-11. 
The synthesis of 3-hydroxyltranscyclooctene was followed the literature149. Briefly, cis-
cyclooctene was converted into 3-bromo derivative 5-12 using NBS, AIBN in carbon tetrachloride 
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CCl4, followed by the hydrolysis under sodium carbonate in the mixture of acetone and water to 
yield the 3-OH cis-cyclooctene 5-13 (Scheme 5-3). 
 
Scheme 5-3. The synthesis of TCO. 
With the cis derivative 5-13 in hand, photochemistry was used to convert it to trans form160. 
Briefly, cis-isomer in ether and hexane was shining with 254 nm light with continuously pumping 
through a column of AgNO3-impregnated silica gel. The trans-cyclooctene is selectively retained 
by the AgNO3-impregnated silica, however, the cis-isomer pass through the column back to the 
reaction flask, where it is photoisomerized and recirculated through the column. Utilizing 
photochemistry, we successfully obtained the equatorial and axial transcyclooctene in 1:1 ratio. 
The synthesis of amplification molecule is shown in Scheme 5-4. The axial TCO was 
converted to active ester, which was used for the coupling reaction without further purification due 
to the poor stability on column. The crude axial TCO active ester was coupled with scaffold under 
NaH in DMF at 0 oC. Unfortunately, the product was not separate due to the low polarity, therefore 
the mixture was directly used for the TBS deprotection. Fortunately, it can be purified after 
deprotecting TBS under TBAF with 60% over 2 steps. The alcohol was converted to the 
corresponding active esters and coupled with fragment to yield the final amplification molecule 
with 65% yield. 
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Scheme 5-4. The synthesis of amplification molecule. 
 With both molecules in hand, the amplification efficiency was analyzed by HPLC. The 
initiator and amplifier were dissolved in 90% DMSO-H2O, followed by the addition of TBAF and 
methylene blue. The reaction vial was shined under 660 nm LED light. The concentration of 
tetrazine was measured at different time using HPLC. The HPLC condition is 100% H2O to 100% 
CH3CN in 15 min, followed by running 100% CH3CN for another 15 min. The reactants and 
products are shown in Figure 5-11. 
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Figure 5-11 The reaction between initiator, trigger and amplifier. 
Several negative controls need to be considered to prove our amplification system. 1) 
initiator + TBAF, there should be a few amount tetrazine released due to the TBS deprotection, 
followed by the electron flow, carbon dioxide escape, cyclization lead to tetrazine release. 2) 
initiator + TBAF + methylene blue + LED, there might be more amount of tetrazine because of 
the oxidization rate is accelerated by methylene blue and LED light. 3) initiator + methylene + 
LED, demonstrates that initiator is stable under LED light and methylene blue. 4) amplifier + 
TBAF, shows that amplifier is stable when treating with TBAF. 5) amplifier + methylene blue + 
LED, proves that methylene blue and LED will not touch the amplifier and lead to false positive 
results. Only initiator + TBAF + amplifier + methylene blue + LED were used, a large amount of 
tetrazine was detected by HPLC, which was shown in Figure 5-12. 
130 
 
Figure 5-12 The concentration of tetrazine detected by HPLC. 
From the Figure 5-12, we can conclude that only trace amount of tetrazine was released 
when initiator was mixed with TBAF. When methylene blue and LED light were employed, the 
amount of tetrazine increased. More methylene blue lead to more tetrazine release. When all the 
molecules were mixed together, a large amount of tetrazine was detected. The figure proves that 
our amplification system works, although the efficiency is not high. Only ~10% of tetrazine was 
released based on calculation. More modifications, such as synthesis of ring promoted self-
immolative spacer and methylation on nitrogen atom of scaffold to yield ~100% release, should 
be done. 
The next set of work was designed to synthesis of a new ring promoted self-immolative 
spacer, as shown in Scheme 5-5. The present of five-member ring in the α position of amine forces 
the formation of 1,3-dimethyl-2-imidazolidinone, thus increase the release yield. The synthesis of 
this new self-immolative spacer started from cyclopentanone, which reacted with benzyl amine to 
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form imine. Without any purification, imine was converted to compound by treating with 
trimethylsilyl cyanide TMSCN with 88% yield over 2 steps. Then cyano group was reduced to 
amine under LiAlH4 in ether with quantitative yield, followed by hydrogenolysis of benzyl group 
using Pd(OH)2/C/H2 in MeOH-HOAc to yield diamine coupound.  Methyl group was installed by 
treating with MeI/NaH in DMF after protecting the diamine with boc group. Then the boc group 
was removed using TFA in DCM, and mono boc was installed again to achieve the final 
compound. 
 
Schemee 5-5. The synthesis of a new self-immolative spaer. 
Recently, Weissleder’s group reported that almost quantitative release was achieved by 
installing a methyl group on the nitrogen atom of the scaffold156. Encouraged by this literature, our 
next modification was aim to install a methyl group on the nitrogen. The similar protocol was used 
to install the methyl group. Briefly, the amine group was protected with boc and NaH/MeI in DMF 
was used to do methylation. After boc deprotection using aqueous H3PO4 in DCM, the new 
scaffold was achieved (Scheme 5-6 top). However, due to the low stability of TBS group in acid, 
the reaction yield is quite low. A new method, reductive amination was used to put the methyl 
group (Scheme 5-6 bottom). 
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Scheme 5-6. The synthesis of N-methyl scaffold.  
The synthesis of new initiator and amplification molecule is in progress. 
5.5 Summary 
We have designed a tetrazine-TCO based bioorthogonal amplification system. The initiator 
and amplifier in the amplification cycle were synthesized successfully, and characterized by 1H, 
13C, COSY and HSQC. The assay demonstrated that our biorthogonal amplification strategy is 
working as detected by HPLC. More efforts should be paid to increase the amplification efficiency. 
To overcome this problem, a new ring promoted self-immolative spacer and N-methylation 
scaffold were synthesized. The synthesis of new initiator and amplification molecule is in progress. 
5.6 Experiment section 
5.6.1 General 
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All chemical reagents were of analytical grade and used as supplied without further 
purification unless indicated. The acidic ion-exchange resin used was Amberlite IR 120 (H+) resin. 
Analytical thin layer chromatography (TLC) was performed on silica gel 230−400 mesh 
(Sicicycle). Plates were visualized under UV light, by staining with acidic CeH8Mo3N2O12 
followed by heating, or both. Column chromatography was performed on silica gel (230−400 
mesh). 1H and 13C NMR spectra were recorded on Bruker 400 MHz spectrometer. Chemical shifts 
are reported in δ (ppm) units using 13C and residual 1H signals from deuterated solvents as 
references. Spectra were analyzed with MestreNova (Mestrelab Research). Electrospray ionization 
mass spectra were recorded on a Micromass Q\T 2 (Waters), and data were analyzed with 
MassLynx 4.0 (Waters) software. Reported yields refer to spectroscopically and 
chromatographically pure compounds that were dried under high vacuum (10−2 mbar) before 
analytical characterization unless otherwise specified.  
5.6.2 General procedure for the preparation of symmetric dihydrotetrazines Nitrile (1.0 
eq) and Zn(OTf)2 (0.05 eq) were mixed together in a round bottom flask under N2. Anhydrous 
hydrazine (2.5 eq) was added dropwise. The reaction mixture was stirred at 65 oC overnight to 
yield the crude dihydrotetrazine. For electron donating substituent dihydrotetrazine, it is used for 
the next reaction without any purification. For electron withdrawing group, the crude was 
subjected to flash column to yield pure dihydrotetrazine. 
5.6.3 General procedure for the synthesis of asymmetric dihydrotetrazine Nitrile 1 (1.0 
eq), nitrile 2 (5.0 eq), and Zn(OTf)2 (0.2 eq) were mixed together in a round bottom flask under 
N2, followed by dropwise addition of anhydrous hydrazine (2.5 eq). The reaction mixture was 
stirred at 65 oC overnight to yield the crude dihydrotetrazine. For electron donating substituent 
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dihydrotetrazine, it is used for the next reaction without any purification. For electron withdrawing 
group, the crude was subjected to flash column to yield pure dihydrotetrazine. 
4-nitrophenyl 3,6-diphenyl-1,2,4,5-tetrazine-1(4H)-carboxylate 
 
To a stirring solution of crude 2,5-diphenyl-1,4-dihydrotetrazine (400 mg, 1.69 mmol) in 
THF at 0 oC under argon, NaH (90 mg, 90%, 3.38 mmol) was added. The reaction mixture was 
stirred at 0 oC for 30 min before adding 4-nitrophenyl chloroformate (511 mg, 2.54 mmol). The 
reaction was allowed to warm to rt and stirred overnight. The solvent was removed under reduced 
pressure, and the residue was subjected to column eluting with hexane/EtOAc (9:1) to yield the 
active ester as yellow solid (339 mg, 0.85 mmol, 50%). 
tert-butyl methyl(2-(N-methyl-3,6-diphenyl-1,4-dihydro-1,2,4,5-tetrazine-1-
carboxamido)ethyl)carbamate 
 
To a stirring solution of active ester (100 mg, 0.25 mmol) in anhydrous DMF at 0 oC, the 
boc-protected linker (70 mg, 0.37 mmol) was added, followed by the addition of DIPEA (87 µL, 
0.50 mmol). The reaction mixture was stirred at 0 oC and was allowed to warm to rt. Upon the 
reaction was completed, EtOAc and H2O were added and the layer was separated. The aqueous 
layer was extracted with EtOAc, and the combined organic layer was wash with brine, dried over 
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Na2SO4, and concentrated to dryness. The residue was subjected to column eluting with 
hexane/EtOAc (7:3) to yield the coupling compound as a yellow oil (81 mg, 0.18 mmol, 72%). 
N-methyl-N-(2-(methylamino)ethyl)-3,6-diphenyl-1,2,4,5-tetrazine-1(4H)-
carboxamide 
 
To a stirring solution of compound (81 mg, 0.18 mmol) in DCM at 0 oC, TFA (0.5 mL) 
was added. The reaction mixture was stirred at 0 oC for 30 min before quenching with Et3N. The 
solvent was removed in vacuo and the residue was put on high vacuum for 2 h, which was directly 
used for the next reaction without further purification. 
4-((tert-butyldimethylsilyl)oxy)benzaldehyde 
 
To a stirring solution of 4-hydroxylbenzaldehyde (2.0 g, 16.38 mmol) in DMF at 0 oC, 
imidazole (2.2 g, 32.76 mmol) was added, followed by the addition of TBSCl (3.0 g, 19.66 mmol). 
The reaction mixture was stirred at rt for 6 h. The solvent was removed under high vacuum and 
the residue was purified with column eluting with hexane/EtOAc (19:1) to yield the titled 
compound as a white solid (3.41 g, 14.4 mmol, 88%). 
(4-((tert-butyldimethylsilyl)oxy)phenyl)methanol 
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To a stirring solution of aldehyde (3.41 g, 14.4 mmol) in MeOH, NaBH4 (163 mg, 4.3 
mmol) was added. The reaction was stirred at rt until the starting material was consumed. The 
reaction was neutralized by H+ resin to PH = 6, and the solvent was removed in vacuo. The residue 
was dissolved in EtOAc and washed with brine. After drying with Na2SO4 and concentration to 
dryness, the residue was purified with column eluting with hexane/EtOAc (5:1) to yield the alcohol 
(2.75 g, 11.52 mmol, 80%). 
4-((tert-butyldimethylsilyl)oxy)benzyl (4-nitrophenyl) carbonate 
 
To a stirring solution of alcohol (1.0 g, 4.19 mmol) in anhydrous DCM at 0 oC, Et3N was 
added (0.87 mL, 6.29 mmol) was added, followed by the addition of 4-nitrophenyl chloromate 
(1.01 g, 5.03 mmol). The reaction mixture was stirred at 0 oC and was allowed to warm to rt. Upon 
the reaction was completed as monitor by TLC, the solvent was removed and the residue was 
subjected to column eluting with hexane/EtOAc (15:1) to yield the active ester (3.35 mmol, 1.35 
g, 80%). 
4-((tert-butyldimethylsilyl)oxy)benzyl methyl(2-(N-methyl-3,6-diphenyl-1,4-dihydro-
1,2,4,5-tetrazine-1-carboxamido)ethyl)carbamate 
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To a stirring solution of fragment (0.18 mmol, assuming 100% yield) in anhydrous DMF 
at 0 oC, active ester (80 mg, 0.20 mmol) was added, followed by the addition of DIPEA (125 µL, 
0.36 mmol). The reaction mixture was stirred at 0 oC and was allowed to warm to rt and stirred 
overnight. The reaction mixture was diluted with EtOAc and H2O, and the layer was separated. 
The aqueous layer was extracted with EtOAc, and the combined organic layer was wash with 
brine, dried over N2SO4 and purified by column eluting with hexane/EtOAc (7:3) to yield the 
initiator as a yellow oil (73 mg, 0.12 mmol. 67%). 
4-nitroisophthalic acid 
 
To a round bottom flask under argon, 2,4-dimethyl-1-nitrobenzene (10 g, 66.15 mmol) and 
200 mL H2O were added, followed by portionwise addition of KMnO4 (52.27 g, 330.75 mmol). 
The reaction mixture was stirred with refluxing for 24 h, then filtered hot through celite. The filtrate 
was acidified with H2SO4, extracted with EtOAc, and dried over Na2SO4. The solvent was 
removed in vacuo to yield the carboxylic acid (8.38g, 39.69 mmol, 60%). 
(4-nitro-1,3-phenylene)dimethanol 
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To a stirring solution of acid (8.38 g, 39.69 mmol) in THF, trimethyl borate (24.75 g, 
238.14 mmol) was added, followed by the dropwise addition of BH3·THF (1 M solution in THF, 
159 mL, 159 mmol). Then the reaction mixture was heated to 50 oC for 2.5 h. The reaction was 
allowed to cool to rt, followed by the addition of 1N HCl. Once the evolution of bubbles ceased, 
brine was added and the layer was separated. The aqueous layer was extracted with EtOAc, and 
the combined layer was dried oved Na2SO4, and concentrated to dryness. The residue was purified 
with column eluting with hexane/EtOAc (1:2) to yield the alcohol (5.82 g, 31.75 mmol, 80%). 
(((4-nitro-1,3-phenylene)bis(methylene))bis(oxy))bis(tert-butyldimethylsilane) 
 
To a stirring solution of alcohol (3.66 g, 20.0 mmol) in DMF at 0 oC, imidazole (4.01 g, 
60.0 mmol) was added, followed by the addition of TBSCl (7.54 g, 50.0 mmol). The reaction 
mixture was stirred at rt overnight, and the solvent was removed under high vacuum. The residue 
was purified using column eluting with hexane/EtOAc (20:1) to yield the titled compound as a 
white syrup (7.0 g, 17.0 mmol, 85%). 
2,4-bis(((tert-butyldimethylsilyl)oxy)methyl)aniline 
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To a stirring solution of compound (1.0 g, 2.43 mmol) in THF and MeOH (1:1), Pd(OH)2/C 
(100 mg) was added. The reaction mixture was stirred for 2 h under H2 balloon. Upon the reaction 
was completed, filter through celite and the filtrate was concentrated to dryness to yield the crude 
amine. The crude compound was purified by column eluting with hexane/EtOAc (19:1) to yield 
the desired amine (835 mg, 2.19 mmol, 90%). 
(Z)-cyclooct-2-en-1-ol 
 
To a stirring solution of cis-cyclooctene (10.0 mL, 77 mmol) in carbon tetrachloride under 
argon, N-Bromosuccinimide (NBS, 10.0 g, 56.2 mmol) and azobisisobutyronitrile (AIBN, 23 mg, 
0.14 mmol) were added. The reaction mixture was stirred under reflux for 2 h. The reaction was 
cooled at 0 °C and the precipitate were removed by filtration. The solvent was rotary vaporized to 
give 3-bromocyclooctene as light yellow oil. The product was subsequently dissolved in a mixture 
of acetone and water. NaHCO3 (10 g, 120 mmol) was added to the solution and the mixture was 
stirred under reflux for 1 h. The mixture was filtered and the filtrate was extracted with Et2O. The 
ether layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by column to yield the titled compound as a light yellow oil (6.8 g, 53.9 mmol, 70%). 
(E)-cyclooct-2-en-1-ol 
 
(Z)-cyclooct-2-enol (8.5 g，67 mmol) and methyl benzoate (9.2 g，67 mmol) was 
dissolved in a mixture of 400 mL Et2O and 800 mL hexane. The solution was irradiated for 24 h 
while it was constantly led through a column containing silica (117 g) treated with AgNO3 (13.19g, 
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77.6 mmol). The column was placed in the dark during the reaction. The column was then washed 
with 500 mL DCM and dried with air. The silica was collected, stirred in a mixture of NH3·H2O 
(500 mL) and DCM (500 mL). The organic layer was separated, and the aqueous layer was 
extracted with DCM (750 mL). The organic layer was combined, dried over Na2SO4, filtered and 
vaporized to give brown thick oil. The crude product was purified by column chromatography 
using hexane/EtOAc (100:1 to 75:1) to give axial isomer (first fraction, 1.84 g, 22%) as colorless 
thick oil and equatorial isomer (second fraction, 1.94 g, 23 %) as light yellow thick oil. 
(E)-cyclooct-2-en-1-yl (4-nitrophenyl) carbonate 
 
To a stirring solution of axial isomer (200 mg，1.58 mmol) and pyridine (188 mg, 2.4 
mmol) in DCM at 0 oC, 4-nitrophenyl chloroformate (384 mg, 1.9 mmol) was added. The reaction 
mixture was allowed to warm to rt and was further stirred in the dark for 3 h and was poured into 
water. The aqueous layer was extracted with Et2O. The combined ether layer was washed with 
aqueous acetic acid (pH=3), saturated aqueous NaHCO3 and saturated aqueous NaCl. The organic 
layer was 
dried over Na2SO4, filtered and the solvent was removed to yield (E)-cyclooct-2-enyl (4-
nitrophenyl) carbonate as a white solid, which was used for the next reaction without further 
purification. 
(E)-cyclooct-2-en-1-yl (2,4-bis(hydroxymethyl)phenyl)carbamate 
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To a stirring solution of compound (50 mg, 0.13 mmol) in anhydrous DMF at 0 oC, NaH 
(4.8 mg, 0.20 mmol) was added. The reaction mixture was stirred at 0 oC for 30 min, followed by 
the addition of active ester (29 mg, 0.10 mmol) in dry DMF. The reaction mixture was stirred at 0 
oC to rt overnight. EtOAc and H2O were added to dilute the reaction, and the layer was separated. 
The aqueous layer was extracted with EtOAc, and the combined organic layer was washed with 
brine, dried over Na2SO4 and concentrated to dryness to yield the crude product, which was used 
directly for the next reaction. The residue was redissolved in anhydrous THF, TBAF (1.0 M in 
THF, 0.5 mL) was added. The reaction mixture was stirred at rt until the starting material was 
consumed. The solvent was removed under reduced pressure, and the residue was purified by 
column to yield the titled compound (18 mg, 60% over 2 steps). 
(E)-cyclooct-2-en-1-yl(2,4-bis((((4-
nitrophenoxy)carbonyl)oxy)methyl)phenyl)carbamate 
 
To a stirring solution of diol (50 mg, 0.16 mmol) in anhydrous DCM at 0 oC, Et3N (89 µL, 
0.64 mmol) was added, followed by the addition of 4-nitrophenyl chloromate (97 mg, 0.48 mmol). 
The reaction mixture was stirred at 0 oC and rt overnight. Upon the reaction was completed, the 
solvent was removed under reduced pressure. The residue was purified by column to yield the 
active ester (76 mg, 75%). 
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To a stirring solution of active ester (50 mg, 0.079 mmol) and fragment (70 mg, 0.20 mmol) 
in anhydrous DMF at 0 oC, DIPEA (70 µL, 0.40 mmol) was added. The reaction mixture was 
stirred at 0 oC to rt overnight. Upon the reaction was completed, EtOAc and H2O were added to 
dilute it and the layer was separated. The aqueous layer was extracted with EtOAc, and the 
combined organic layer was washed with brine, dried over Na2SO4 and concentrated to dry. The 
residue was purified by column to yield the amplification molecule (53 mg, 0.051 mmol, 65%). 
1-(benzylamino)cyclopentane-1-carbonitrile 
 
Cyclopentanone (2.0 g, 23.78 mmol) was dissolved in benzylamine (3.5 mL) and the 
resulting mixture was stirred for 30 min at rt. Then TMSCN (3.6 mL) was added dropwise and 
then stirred for 1 h.  The solvent was removed under reduced pressure, and the residue was purified 
by flash chromatography on silica gel eluting with hexane/EtOAc (100:1) to yield the titled 
compound as a colorless oil (4.19 g, 20.92 mmol, 88%). 
1-(aminomethyl)-N-benzylcyclopentan-1-amine 
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To a stirring solution of compound (4.0 g, 19.97 mmol) in anhydrous Et2O at 0 oC, LiAlH4 
(3.03 g, 79.8 mmol) was added portionwise. The reaction mixture was stirred at 0 oC for 1 h and 
was allowed to warm to rt. Then 3 mL H2O,3 mL of 15% KOH and finally 11 mL of H2O are 
added dropwise while maintaining the temperature less than 15° C. Filter through celite and the 
filtrate was dried over Na2SO4. Concentrate to dryness to yield the titled compound as a yellow oil 
(3.96 g, 19.37 mmol, 97%). 
1-(aminomethyl)cyclopentan-1-amine 
 
To a stirring solution of compound (3.96 g, 19.37 mmol) in the mixture HOAc and MeOH, 
Pd(OH)2 (792 mg) was added. The reaction mixture was stirred for 24 h under treating with H2. 
Upon the reaction was completed, filter through the celite and the filtrate was removed under 
reduced pressure to yield diamine compound as a yellow oil (1.66 g, 14.53 mmol, 75%). 
tert-butyl (1-(((tert-butoxycarbonyl)amino)methyl)cyclopentyl)carbamate 
 
To a stirring solution of diamine compound (1.66 g, 14.53 mmol) in anhydrous THF, Et3N 
(6.0 mL, 43.59 mmol) was added, followed by the addition of Boc2O (7.93 g, 36.33 mmol). The 
reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure and 
the residue was purified on column eluting with hexane/EtOAc (10:1) to yield the titled compound 
(3.88 g, 12.35 mmol). 
tert-butyl (1-(((tert-
butoxycarbonyl)(methyl)amino)methyl)cyclopentyl)(methyl)carbamate 
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To a stirring solution of compound (3.5 g, 11.13 mmol) in anhydrous DMF, NaH (890 mg, 
90%, 33.39 mmol) was added at 0 oC. The reaction mixture was stirred for 30 min before adding 
MeI (1.73 mL, 27.83 mmol). The resulting mixture was stirred at 0 oC to rt overnight. EtOAc and 
H2O were added and the layer was separated. The combined organic layer was washed with brine, 
dried over Na2SO4, and concentrated to dryness. The residue was purified by column eluting with 
hexane/EtOAc (10:1) to yield the titled compound (3.05 g, 8.90 mmol, 80%). 
tert-butyl methyl((1-(methylamino)cyclopentyl)methyl)carbamate 
 
To a stirring solution of di-boc compound (3.0 g, 8.76 mmol) in DCM at rt, TFA (3.0 mL) 
was added. The reaction mixture was stirred at rt for 1h. Then the solvent was removed under 
reduced pressure, and the residue was put on high vacuum for 2 h, which was used for next reaction 
without further purification. The residue was dissolved in anhydrous THF, Et3N (1.83 mL, 13.14 
mmol) was added, followed by the addition of Boc2O (1.91 g, 8.76 mmol). The reaction mixture 
was stirred at rt for 6 h. Then the solvent was removed in vacuo, and the residue was purified by 
column eluting with 100% EtOAc to yield the new self-immolative spacer as a yellow oil (1.27 g, 
5.26 mmol, 60%). 
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